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IMMUNOGENICITY OF RECOMBINANT HS ABA392 PROTEIN VACCINE 
AGAINST HAEMORRHAGIC SEPTICAEMIA IN ANIMAL MODEL 
     ABSTRACT 
Haemorrhagic septicaemia (HS) outbreak has a major impact in Asian countries, 
where farmers encounter economic lost due to death and low milk production. HS 
occurred most commonly in cattle and buffaloes. The first HS outbreak reported in 
Malaysia was in the year 1900 which caused huge lost to the meat and dairy 
industry. Pasteurella multocida has a pathogenic potential in vertebrate animals. P. 
multocida serotype B: 2 is the etiology for HS in Asia thus contribute highest mortality 
rate of cattle and buffaloes. There are four types of vaccine used in all the countries 
namely, alum precipitated vaccine, broth bacterins, aluminum hydroxide gel vaccine 
and oil adjuvant vaccine (OAV). The function of DNA recombinant technology such as 
gene cloning and expression to produce recombinant proteins from P. multocida, could 
trigger immune response and provide protective immunity to the administered animal. 
The recombinant clone ABA392 which used in this study was derived from P. 
multocida serotype B strain 202 (PMB202). ABA392 gene was successfully cloned into 
pET-30a an expression vector and known as ABA392/pET30a. The size of expressed 
protein was determined as ~32 kDa and confirmed via immunoblotting. The protein was 
further purified using Immobilized Affinity Chromatography (IMAC) technique. The 
purified protein was tested on rats for the immunogenicity along with positive and 
negative control groups. Blood was collected weekly for 7 weeks consistently. Enzyme-
Linked Immunosorbent Assay (ELISA), Total White Blood Count (TWBC), Renal 
Function Test (RFT) and Liver Function Test (LFT) were performed. Lung, heart, liver 
and kidney organs were collected and processed for histopathology analysis. No 
significant changes were observed in the entire organs from each group. The purified 
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protein from recombinant clone ABA392/pET-30a has induced high titer antibody 
compared to positive and negative group. Total white blood count shows leukocytosis. 
The RFT and LFT were in normal values in the vaccinated group. Recombinant clone 
ABA392/pET-30a has been expressed purified and has been tested on laboratory rat. 
Since the expressed protein has the capability to provoke immune response, challenge 
studies using P. multocida serotype B: 2 against this protein are required to enhance the 
efficient of this protein as a vaccine against HS in future. 
Keywords: haemorrhagic septicaemia, Pasteurella multocida serotype B: 2,  
        recombinant vaccine, recombinant clone ABA392 and protein vaccine. 
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KEIMUNOGENAN REKOMBINAN HS ABA392 SEBAGAI VAKSIN SUBUNIT 
MELAWAN HAWAR BERDARAH DALAM MODEL HAIWAN 
ABSTRAK 
Wabak hawar berdarah memberi kesan yang mendalam kepada negara Asia dimana 
di mana para penternak lembu terpaksa menghadapi kegawatan ekonomi disebabkan 
kematian lembu-lembu dan pengurangan dalam pengeluaran susu daripada haiwan 
ternakan mereka. Hawar berdarah dihidapi oleh lembu and kerbau secara umum. 
 Wabak hawar berdarah yang pertama direkod di Malaysia pada tahun 1900 yang 
menyebabkan kerugian yang amat besar pada industri tenusu. Pasteurella multocida 
memberi kesan patogenik dalam haiwan vertebrata. P. multocida serojenis B: 2 
merupakan etiologi utama yang menyebabkan hawar berdarah di Asia di samping 
menyumbang kadar kematian yang tinggi pada lembu dan kerbau. Terdapat empat jenis 
vaksin iaitu vaksin daripada bakterin sendiri, vaksin daripada alum persipitasi, vaksin 
gel aluminium hidroksida dan vaksin disediakan menggunakan adjuvan minyak. Fungsi 
teknologi rekombinan DNA seperti pengklonan gen and ekspresi protein rekombinan 
daripada P. multocida boleh mencetuskan respon imun dan memberi perlindungan imun 
kepada haiwan yang diberi vaksin. Rekombinan klon ABA392 yang digunakan dalam 
penyelidikan ini diperolehi daripada P. multocida serojenis B strain 202 (PMB202). 
Gen ABA392 telah berjaya diklonkan bersama vektor protein pET-30a dan dikenali 
sebagai ABA392/pET30a. Size protein yang diekspresi dapat diketahui iaitu ~32 kDa 
dan disahkan melalui kaedah imunoblot. Protein yang diekspresi dari rekombinan klon 
in telah dikaji ke atas tikus makmal untuk mengetahui tahap keimunan bersama 
kumpulan kawalan positif dan negatif. Darah telah diambil setiap minggu sehingga 
minggu ketujuh secara konsisten. ELISA (“Enzyme-Linked Immunosorbent Assay”), 
kiraan sel darah putih, fungsi buah pinggang dan hati turut dianalisis. Organ seperti 
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paru-paru, jantung, hati dan buah pinggang turut dikumpul dan diproses melalui teknik 
histopatologi. Tiada perubahan diperhatikan pada organ-organ yang diproses dari setiap 
kumpulan. Protein dari klon ABA392/pET30a dapat meningkatkan kadar antibodi titer 
apabila dibandingkan dengan kumpulan kawalan positif dan negatif. Kiraan sel darah 
putih menunjukkan leukositosis. Nilai fungsi buah pinggang dan hati berada dalam 
bacaan yang normal. Rekombinan klon, ABA392/pET30a telah diekspresi, disaring dan 
telah dikaji ke atas tikus makmal. Di mana protein dari rekombinan klon ini dapat 
mencetuskan tindak balas immuniti dan boleh dikaji secara mendalam sebagai vaksin. 
Dengan penghasilan vaksin subunit ini, dipercaya bahawa vaksin ini dapat 
mengurangkan kadar hawar berdarah pada haiwan-haiwan ternakan pada masa yang 
akan datang. 
Kata kunci: hawar berdarah, Pasteruella multocida serojenis B: 2, vaksin rekombinan, 
          rekombinan klon ABA392 dan vaksin subunit.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Haemorrhagic Septicaemia (HS) 
Bacterial infection causes severe disease outbreak and spread rapidly among 
domesticated animals. Haemorrhagic septicaemia (HS) is known as a form of 
pasteurellosis which affect mainly water buffalo and cattle. HS outbreak has a major 
impact in Asian countries, where farmers encounter economic lost due to death and low 
milk production. HS occurred most commonly in cattle and buffaloes. HS is endemic 
and has a significant economic impact in Asian countries such as China, Bhutan, 
Indonesia, India, Myanmar, Mongolia Philippine, Malaysia and Sri Lanka since these 
countries own large population of cattle and buffaloes (Ghaffar et al., 2016). P. 
multocida causes HS in cattle and buffaloes, infect with enzootic bronchopneumonia in 
sheep meanwhile causes snuffles and atrophic rhinitis respectively in rabbit and swine 
(Harper et al., 2012). The first HS outbreak reported in Malaysia was in the year 1900 
which caused huge lost to the meat and dairy industry (Corrongean, 1902). Over the 
years the outbreak of HS in the peninsular of Malaysia causing high mortality due to the 
lack of vaccination and inefficient veterinary services (Bisht et al., 2006). In a decade 
from 1995 to 2005 a total of 47 outbreaks of HS have been reported where 8 to 11 
outbreaks were reported in Perak, Kelantan, Terengganu and Pahang, meanwhile 1 to 5 
outbreaks in Penang, Kedah, Negeri Sembilan and Melaka (Annas et al., 2014) (Figure 
1.1). HS outbreak was confirmed through post mortem among buffaloes and cattle in 
West Bengal (Mitra et al., 2013).  
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1.2 P. multocida and Current Vaccination 
P. multocida has a pathogenic potential in vertebrate animals. P. multocida serotype 
B: 2 is the etiology for HS in Asia thus contribute highest mortality rate of cattle and 
buffaloes (Shivachandra et al., 2011). 
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Figure 1.1: Incidence of HS outbreaks according to state and year throughout 1995 to 
2005 in Peninsular Malaysia (Hussaini, 2009)  
Antibiotic treatment was considered to control the infection but, the effectiveness of the 
antimicrobial agent was limited by the increased of antimicrobial resistance of P. 
multocida (Noor Masyitah Jumahat et al., 2015). Infection from P. multocida can cause 
a serious outbreak and affect domestic animals and prevention is recommended to 
control this disease as the mode of current treatment is complicated and ineffective. 
There are four types of vaccine used in all the countries namely, alum precipitated 
vaccine, broth bacterins, aluminum hydroxide gel vaccine and oil adjuvant vaccine 
(OAV) (Qureshi & Saxena, 2014). These types of vaccines consider as the first 
generation vaccine (Ahmad et al., 2014). Each of this vaccine has its advantage and 
limitation (Hussaini et al., 2012). Bacterin is the simplest form of vaccine, which 
consists of whole cell inactivated cultures but, the antibody response towards this 
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vaccine was very poor since the immunity last for less than 2 months. Alum precipitated 
and aluminium hydroxide gel vaccine are most extensively used but only able to 
provide stable immunity approximately six months. The first OAV against HS was 
developed in 1950s which contains water-in-oil emulsion of dense broth culture and 
high mineral oil. OAV gave protection up to 9 months and required annual re-
vaccinations (Sotoodehnia et al., 2005). Thus, a long term effective vaccine is required 
to prevent this HS globally. Regardless of the wide availability of vaccination in the 
market, the quest a suitable and broadly protective with long-lasting immunity HS 
vaccine is still growing (Shivachandra et al., 2011). Recently the development of 
recombinant vaccine may probably reform a positive result for the next generation 
vaccines (Ahmad, 2014). Recombinant vaccine has proved to be safe since it conferred 
equitable high titer against homologous challenge and able to induce high humoral and 
cellular response (Ahmad et al., 2014). The function of DNA recombinant technology 
such as gene cloning and expression to produce recombinant proteins from P. 
multocida, could trigger immune response and provide protective immunity to the 
administered animal. Potential virulence genes in P. multocida can be targeted for the 
production of protein subunit vaccine. The current appropriation of guidelines by the 
Office International des Epizooties (OIE) on the detail for immunizations and analytic 
natural for HS ought to give the fundamental specialized stage to the generation and 
quality confirmation of HS antibodies (OIE, 2005). The primary trial of recombinant 
antibody was created against P. multocida that cause rhinitis in pig utilizing its own 
particular toxin (Bording et al., 1994).  
1.3 The Recombinant Clone ABA392 and pET-30a Vector 
The recombinant clone ABA392 which used in this study was derived from P. 
multocida serotype B strain 202 (PMB202) that was isolated by Veterinary Diagnostic 
Laboratory, Petaling Jaya, and Selangor in 1993 (Salmah Ismail, 1997). From the 
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previous results, recombinant clone ABA392 might harbor a gene that has the capability 
of triggering the immune system of the administrated animal and shield it from HS 
disease.  Previously, the potential of recombinant clone ABA392 as a vaccine candidate 
against HS has been investigated and reported in mice model (Hussaini, 2009; Salmah 
Ismail et al., 2010). pET-30a is a bacterial expression vector with T7 promoter, 
kanamycin resistant and multiple cloning sites that was establish for the cloning and 
expression of recombinant protein in E. coli. This vector was chosen for the study 
mainly because of its efficiency in producing high level of protein in short span of time. 
The produced recombinant protein will be used as one of a vaccine candidate for 
treating HS. 
1.4 Problem Statement  
HS is an acute and cause lethal in cattle and water buffaloes which cause by two 
specific serotype of P. multocida B2 and E2. HS is known as Pasteurellosis and has 
worldwide distribution including Malaysia and a significant loss in economically 
especially in dairy industry (Annas et al., 2014). Treatment is significant when treated 
once the sign of HS appeared in the early stage (Benkirane & De Alwis, 2002). There 
are few general antibiotic such as oxy-tetracycline, co-trimoxazole or combination of 
penicillin with other antibiotic like streptomycin or sulphaquinoxaline. However, P. 
multocida have developed resistant towards this antibiotic in the recent years which 
increase the high morbidity and mortality (Shivachandra et al., 2011). P. multocida has 
also gradually developed resistance to sulfadiazine on of the common antibiotic to 
control HS in the field (Kumar et al., 2009). In order to control HS, research activities 
begin to more concentrate on prevention trough vaccine development and vaccination in 
many countries including Malaysia but the outbreak of HS and death from HS is still 
inevitable.  
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Good biosecurity can be a key in controlling or preventing HS in domestic animals.  
A wide range of vaccine have been developed however they provide limited protection 
with certain disadvantage such as endotoxic shock. Thus, recombinant protein will be an 
effective vaccine component in treating HS since it does need adjuvant. An 
experimental study on animal models will be performed as to check the potential of the 
expressed protein from newly constructed recombinant clone ABA392/pET-30a as a 
protein vaccine by analyzing its immunogenicity and lethality. These studies will allow 
the production of protein vaccine produced to be potentially used in treating HS that is 
caused by P. multocida, not only in Malaysia but globally as well.  
1.5 Objectives of the Study  
It was found that the recombinant clone ABA392 has an immunogenic factor and 
could be used as vaccine in future (Hussaini et al., 2011). Since the HS determinant is 
yet to be reported or discovered elsewhere, it is great interest to conduct this study with 
the aim to evaluate the immunogenic potential and protective efficacy of recombinant 
protein ABA392 in rats, mice, cattle and calves. Therefore, there objection of the study 
are as follows: 
(1) To test the DNA insert stability of recombinant clone ABA392/pET-30a 
(2) To determine the lethality test of recombinant clone ABA392/pET-30a 
rats. 
(3) To express the extracellular protein of the recombinant clone 
ABA392/pET-30a and test its toxicity in laboratory animals.  
(4) To evaluate immunogenicity and access histopathological effects in 
vaccinated laboratory animals against HS 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Haemorrhagic Septicaemia (HS) 
Haemorrhagic septicaemia (HS) can cause a huge loss in food industry as these 
ruminants are the main producer of dairy products and meats (Abdullah et al., 2013). 
HS is characterized as an acute, fatal and septicemic disease which caused by 
Pasteurella multocida serotype B: 2, a gram negative coccobacillus (Chung et al., 
2015). HS occurred most commonly in cattle and buffaloes whereby buffaloes are more 
prone to this disease. Poor in management of husbandry conditions is where this disease 
is happened to occur (De Alwis, 1999). HS classified as a List B disease by the Office 
International des Epizooties (OIE) as a primary pasteurellosis with 100% mortality in 
infected animals in endemic areas of Africa and Asia. It arise as a major bacterial 
disease to economically important of livestock (Benkirane & De Alwis, 2002). It is 
caused by two specific serotypes of P. multocida designated B: 2 (Asian serotype) and 
E: 2 (African serotype) (Shivachandra et al., 2011).  
2.2 Haemorrhagic Septicaemia (HS) in Worldwide Occurrence and   
Distribution 
   Haemorrhagic septicaemia (HS) can be considered as one of the important disease 
that affect bovines not only in South Asia but, it also occur in Middle and Eastern 
countries and the worst outbreak can be seen during rainy season (Khan et al., 2006; 
Mitra et al., 2013). There are also significant reports of HS outbreaks in several Africa 
regions and South America; however, there were no cases reported in Western Europe, 
Oceania and Canada meanwhile, in Pakistan HS is considered significantly economic 
loss with 34.1% of all affected animal died due to HS (FAO, 1991). The disease had 
been suspected in Kuwait and Qatar but the agent and serotyping has not been 
confirmed. However, there is record of the disease on the past in Singapore, Hong Kong 
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and Israel and currently these countries are free from this disease including Japan and 
Jordan (Benkirane & De Alwis, 2002). In Iran, this disease occurs partially in the north, 
north-east and south where 1,200,000 doses of vaccine are administered in cattle and 
buffaloes each year (Tabatabaei et al., 2007). There was an incident and death by HS 
which revealed through clinical diagnosis in some of the farm in Karachi, Pakistan 
(Moustafa et al., 2012). Mitra et al. (2013), has reported that there was HS outbreak at 
West Bengal, India on June and July 2013 where 52 of affected animals and died before 
treatment. Pasteurella multocida was isolated from nasopharyngeal and lungs of dead 
calves from January 2013 to March 2014 in Egypt (El-Jakee et al., 2015).  
2.3 Haemorrhagic Septicaemia (HS) in Malaysia 
HS outbreak has a major impact in Asian countries, where farmers encounter 
economic lost due to death and low milk production (De Alwis, 1999). Between years 
1995 to 2005, a total of 47 outbreaks have been reported. This outbreak were recorded 
almost every year excluding the year of 2004 whereby year 1995 and 2000 show the 
highest outbreak occurred (Figure 2.1). In year 2000, the HS outbreaks in Terengganu 
and Pahang were at its peak along with Nipah virus incident. (Figure 2.1) (Kamarudin, 
2005). In 2003, HS outbreak occurred in Perak due to several factors such as the 
immune status of herd and season changes (Moustafa et al., 2013). All isolates from 
Malaysian outbreaks were found to be P. multocida serotype B: 2. HS affects cattle and 
buffaloes where buffaloes are more affected compare to cattle as this can be seen in 
Figure 2.2. In February 2006 in Pasir Mas, Kelantan, HS outbreak was recorded; 
whereby 77 buffaloes were found dead (Lim, 2006). In May 2008, Mingguan Malaysia 
newspaper reported another HS outbreak in Rantau Panjang, Kelantan. The reason 
behind the outbreak was probably due to higher moisture content during the rainy 
season, poor living and the physical condition of the livestock. In Malaysia, an average 
of 360 heads of infected cattle and buffaloes are killed; approximately 1000 heads in 
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Philippine, Myanmar and Cambodia.  Meanwhile 600 heads and 285 heads are killed in 
India and Sri Lanka respectively (Saad, 2013). The latest HS cases reported were 
occurred in Kuala Terengganu and Marang on May 2017 whereby a total of 245 
including cattle and buffaloes were died of HS (Appendix A).  
 
 
Figure 2.1: Number of HS cases according to the state throughout year 1995 to 2005 
(Hussaini, 2009) 
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Figure 2.2: HS cases according to animal species from the year 1995 to 2005 (Hussaini, 
2009) 
2.4 History of Genus Pasteurella 
P. multocida was first discovered by Rosenbusch and Merchant in 1939 and 
subsequently their taxonomy had been reclassified by Mutters in 1985. In 1989, Rimler 
and Rhoades define P. multocida as a pathogen in animals that colonize in birds and 
mammal (Mutters et al., 1989). Micrococcus gallicidus was the first scientific name 
given to this species which later different genera was given including “Bacterium”, 
“Octopsis”, “Coccobacillus” and “Eucystia”. Trevisan has given a new generic name in 
1887 as Pasteurella in conjunction name of Pasteur. 
2.5 Colony and biochemical identification of P. multocida 
P. multocida is a small gram negative, non-motile and non-spore forming 
coccobacillus showing bipolar staining. P. multocida is able to grow at 37°C on blood 
agar and produce small non-hemolytic colonies accompanied by mousy odor 
characteristic due to the metabolic products. The colonies appear to be whitish, opaque, 
circular and translucent (Haq & Abdullah, 2015). Since it is also facultative anaerobe, it 
is oxidase-positive, catalase-positive and ferments large number carbohydrates in 
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anaerobic conditions. P. multocida can be grown in nutrient agar but blood agar and 
chocolate agar is more preferable and it doesn’t grow on macconkey agar, ss agar and 
nutrient broth which contain sodium chloride in small percentage. P. multocida also 
able to ferment mannitol, sorbitol, galactose, fructose, mannose, dextrose meanwhile, 
unable to ferment dulcitol, maltose and lactose. The ability to produce acid from 
mannitol, mannose and glucose and disability to produce gas from inositol, arabinose, 
dulcitol and inoline can be characterized as P. multocida (Haq & Abdullah, 2015). 
Analytical profile index (API) has been developed to identify P. multocida. Although 
this technique was rapid and easy due the misdiagnosis of strains and costly it was not 
use as basic test identification. (Dziva et al., 2008).  
2.6 Types of Infection of P. multocida 
P. multocida is a pathogenic bacterium that commonly found in wide range of 
vertebrate animal hosts and it causes the pasteurellosis infection. P. multocida also 
infect human through the bites from pets like cat or dog (Giordano et al., 2015 and 
Akahane et al., 2011). The Pasteurella species generally colonize the upper respiratory 
tract and oropharynx (Krol et al., 2011). P. multocida causes hemorrhagic septicemia 
(HS) in both cattle and buffaloes, enzootic bronchopneumonia in cattle and sheep, 
atrophic rhinitis in swine and snuffles in rabbit. P. multocida infection in human 
through pets like dogs or cats can cause cellulitis and lymphangitis and may get 
complicated with abscess formation and septic arthritis (Ewers et al., 2006). 
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2.7 Serogroups of P. multocida 
P. multocida consist of 5 serogroup which known as A, B, D, E and F based on the 
antigenicity capsule and 1-16 serotype according to the Lipopolysaccharide (LPS) 
antigens based on somatic typing. Thus, capsular and somatic typing is designated to 
identify the serotype of P. multocida (Johnson et al., 2013). Each serogroup cause 
difference types of infection and serogroup B is generally related to cause HS (Boyce et 
al., 2000). Besides the capsular and somatic typing, serotypes are also categorized based 
on the host, different infection and geographical distribution. P. multocida serotype A is 
the cause of fowl cholera and the virulence factor is the capsular material which forms 
from the composition of hyaluronic acid. It is heavily capsulated which can resist to 
phagocytosis P. multocida serogroup B and E can found in cattle and the major cause of 
HS (Nsofor et al., 2006).  P. multocida serogroup D is responsible for atrophic rhinitis 
in pigs by expressing P. multocida toxin (PMT) (Harper et al., 2006). Serogroup F is the 
cause of fowl cholera which was initially isolated from turkeys in USA and birds 
originated from North America (Jaglic et al., 2005).   
Table 2.1: Classification of P. multocida based on different serogroup and its 
disease (Jaglic et al., 2005) 
 
Serogroup Disease Infected 
animals 
Geographical 
distribution 
A Various 
infection 
Domestic 
animals 
World widely 
B HS Cattle and wild 
ruminants 
Tropic areas 
D Various 
infection 
Domestic 
animals 
World widely 
E HS Cattle and wild 
ruminants 
Tropic areas 
F Fowl cholera Avian North America 
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2.8 Identification P. multocida by Serogroup 
Indirect hemagglutination test is one of the tests used to identify five distinct capsular 
serogroup and also serological differences. Serogroup A is responsive to the activity of 
hyaluronidase. Nuclear magnetic resonance research indicate that major polysaccharide 
component in the capsule is composition of hyaluronic acid. Meanwhile, capsular 
material of serogroup B and F are identified through mucopolysaccharides action or 
production of chondroitin sulfate and heparin. Production of chondroitin or more to 
chondroitin-like polysaccharides capsule in P. multocida serogroup F can be confirmed 
by carbohydrate analysis. In P. multocida serogroup B the monosaccharide analysis 
shows that the capsular polysaccharide is composed by mannose, arabinose and 
galactose. The chemical component in serogroup E is still remaining unknown. 
Multiples capsular Polymerase Chain Reaction (PCR) typing system is a useful tool in 
identifying capsular serotyping system in P. multocida. This system is rapid and highly 
specific in analyzing capsular serotyping from the isolates of different geographical 
distribution (Towsend et al., 2001). HS-causing serogroup B-specific PCR assays is a 
significance tool to identify P. multocida serogroup B that causing HS. Toxigenic P. 
multocida can be detected rapidly through colony lift-hybridisation assay (Hunt, 2000). 
Restriction (REA) analysis is also used in differentiating HS isolates meanwhile PCR 
fingerprinting, ribotyping and pulsed-field gel electrophoresis (PFGE) can be used in 
identifying serogroup of P. multocida.  P. multocida serogroup can be differentiated by 
multi-locus sequence typing (MLST) and gene sequencing based on the specific gene 
loci (Benkirane & De Alwis, 2002 & Shivachandra, 2011). Access to PCR facility, 
Random Amplified Polymorphic DNA (RAPD) or repetitive sequence PCR is also 
useful in identifying of P. multocida serogroup. Due to the low level of systemic 
immunity, the immunological assay was not considered as a routine in identification of 
P. multocida serogroup (Hassan et al., 2016). ELISA was one of immunological assay 
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that have been used to identify P. multocida serogroup A, B, D, E and F (Dziva et al., 
2008). Ranjan et al. (2011) stated currently real time PCR become highly sensitive and 
specific in detecting P. multocida especially field sample.  
2.9 Virulence Factor and Pathogenesis HS 
A virulent factor has an important role in mechanism of P. multocida infection. P. 
multocida strains were tested based two different strain which known as virulent and 
avirulent. Testing was made by administering these two different strains into the animal 
host (Boyce & Adler, 2000). However, it shows that virulent strain survived and 
multiplied on infected pharyngeal mucosa or intravascular of the exposed host (Boyce 
& Adler, 2000). P. multocida consist of 5 serogroup A, B, D, E and F and each of this 
serogroup was determined through the antigenicity of the capsule meanwhile serotype 
1-16 was classified through lipopolysaccharide (LPS) antigen (Boyce et al., 2000; 
Towsend et al., 2001; Shivachandra et al., 2011). Polysaccharides are highly hydrated 
polyanionic and linked to phospholipid. This polysaccharide is a common substance that 
can be found in P. multocida. Polysaccharides is built by repetitive monosaccharide and 
attached together by glycosidic linkage. Meanwhile, this glycosidic linkages is formed 
by monosaccharide hydroxyl groups. Moreover, when a disease is caused by P. 
multocida, polysaccharides are more likely have an important role in the mechanism of 
the disease.  
The capsule not only protects the bacteria from dehydrating and transports it from 
host to host but also strengthen the bacteria to survive in the environment. (Boyce et al., 
2000). Studies indicate among the encapsulated and un-capsulated strains, encapsulated 
strains are expected to be more resistant towards phagocytosis. Besides this, both 
encapsulated and un-capsulated P. multocida B: 2 show differences in sensitivity 
towards phagocytosis. Antiphagocytic activity can be seen in the capsule that belongs to 
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pathogenic bacteria. The negative charge which released from the capsule join along 
with the bacteria and phagocyte thus disruption in phagocytosis activity against the 
bacteria occurs. In most cases, Gram negative pathogenic bacteria have increased the 
resistance towards bactericidal complement and it is commonly related to capsule 
expression. Comparison between acapsular and capsular strain, the acapsular strain of P. 
multocida B: 2 appear to be less virulent. There is two types of LPS glycoform are 
produce by P. multocida, glycoform A and B. The outer core of this glycoform is 
similar meanwhile the inner core different. The production of third type LPS glycoform 
have been observed in some P. multocida strain but, it was expressed in low level. The 
interaction between LPS and host’s innate immune systems can cause endotoxic shock 
thus leads to mortality of the host (Raetz & Whitfield, 2002). The advantage of knowing 
the LPS structure can be applied during the development of rapid molecular method and 
vaccine development as well (Harper et al., 2011). P. multocida infection can be caused 
by the protease that secreted bacteria itself. This happens because the secreted protease 
has the capability to cleave immunoglobulin G (IgG). In 2003, Cullen et al. (2003) 
stated the outer membrane lipoprotein of P. multocida can be considered as one of a 
virulence factor and has the potential to provide protective immunity. Adhesive 
properties which can be found in fimbrial protein on P. multocida help the bacteria to 
colonize in the host and leads to infection (Saad, 2013). 
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Table 2.2: Disease and virulent factor from different serogroup of P. multocida     
     (Wilkie et al., 2012) 
 
Disease Serogroup Affected 
Animals 
Virulent Factors 
Snuffles A, D Pigs, Rabbit Not Established 
Enzootic 
Pneumonia, 
Shipping fever 
A,  D , F (rare) Cattles, sheep, 
pigs 
Co-infection with 
other bacteria or 
viral species 
important 
Haemorrhagic 
Septicaemia 
B, E Cattle, pigs, 
goats and 
buffalo 
Capsule, 
Fimbriae, 
Filamentous 
haemaglutinin 
Avian Cholera A, F, D (rare) Chicken, turkey, 
ducks 
Capsule, LPS, 
Iron acquisition 
protein, Filamentous 
haemaglutinin 
Atrophic rhinitis D, A (rare) Pigs, rabbit P.multocida toxin 
(PMT) 
 
2.10 Etiology and Pathogenesis HS 
HS is characterised by terminal septicaemia and shock in cattle and buffaloes (Ataei 
et al., 2009). P. multocida type B: 2 and E: 5 is the main etiology that causes HS is in 
Asian and African countries respectively (Ranjan et al., 2011).  Host is infected through 
the inhalation and ingestion of the agent resulting in septicaemia and multiple-organ 
haemorrhages. Transmission P. multocida via gastrointestinal or urinary tracts is also 
another possible route, but still remain without scientific confirmation (Annas et al., 
2014). HS affect both cattle and buffaloes whereby buffaloes encounter the highest 
mortality rate. The outbreak of HS happens usually when latent carriers infect the 
nasopharynx and thus activated the virulent bacteria. P. multocida cannot infect lungs 
but stress and other factors including climate changes or malnutrition can weaken lung’s 
defense system. The occurrence of active and inflammatory substance may lead the 
death of macrophage in lungs (Khan et al., 2011). Poor in the management of husbandry 
conditions is where this disease happen to occur. The clinical symptoms are usually 
high temperature, loss of appetite, nasal discharged, increased salivation, labored 
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breathing and swelling in the submandibular region meanwhile death is usually rapid 
and mortality once the animal is fully infected (De Alwis, 1999). An organism that 
causes HS doesn’t survive outside the animal body and usually it tends to spread during 
wet season. High buffalo population, humid conditions, free grassland system of 
management and paddocked together is usually associated with higher incidence of HS 
apart than inhalation or ingestion of P. multocida. 
2.11 Diagnosis of HS 
The diagnosis of HS may include the combination of clinical signs and gross 
pathological lesions and these measurements are important, since they can be used as 
preventive measures to control the disease from spreading. Biochemical, serological test 
and molecular method are the methods that have been established as diagnostic test for 
HS. Rapid slide agglutination, indirect hemagglutintion or non-serological test including 
acriflavine, flocculation or hyaluronidase may be employed to identify the serogroups. 
Whereas, molecular method which consist of polymerase chain reaction (PCR), 
ribotyping or restriction endonuclease analysis (REA) can be convincing routine to 
diagnosis HS since these methods can be utilized to differentiate the serotypes 
(Benkirane & De Alwis, 2002). 
2.12 Treating HS 
Antibiotic can be used as a primary treatment since bacteria is the etiology of HS but, 
this treatment can be applied at the early of stage of infection. In the primitive 
husbandry system, the early detection of this disease has always been neglected. 
Meanwhile, well-organized farm always be alert by checking rectal temperatures 
regularly (Benkirane & De Alwis, 2002). Recently, antibiotic are becoming resistance 
towards HS and it is becoming crucial in treating HS. In order to control the resistance 
strain, a new antibiotic has been introduced. However, the new antibiotic is very 
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restricted and costly (Xiao et al., 2016; Shivachandara et al., 2011). Vaccination is still 
leading method to prevent HS.  
2.13  Vaccination Approach as a Method of HS Prevention 
In order to prevent HS, vaccination on accessible attempt have been practiced. In 
most of the affected countries, the various formulation of available HS vaccine has been 
used in order to prevent HS. In 2004, Biswas et al. stated that even with the proper 
vaccination schedule HS still can occur. Due to this report, a proper vaccination strategy 
using the current vaccine needs to be remodel. The first effective vaccine was 
introduced in 1978 (Chandrasekaran & Yeap, 1978). In early stage, traditional vaccine 
has been used to exterminate the HS infection or to provide long lasting immunity (De 
alwis, 1999). Earlier studies in 1991 have shown that monoclonal antibodies (mAbs) 
help in two ways to prevent HS, by increasing the immunity against OMP and prevent 
the bacteria from proliferating in the lungs (Lu et al., 1991). Besides OMP, outer 
membrane protein H (OmpH), ammonium sulphate perceptible protein fraction and 
mixture OMP’s of P. multocida was effective against P. multocida infection (Dabo et 
al., 2007; Adler et al., 1999; Srivastava et al., 1999; Marandi et al., 1997).  
Vaccination is still being an efficient method to protect farm animals against P. 
multocida. To provoke the immune response, whole inactivated or killed bacteria are 
injected to the farm animals and this vaccine acted as whole cell vaccine. This type of 
vaccine called a first generation vaccine (Ahmad et al., 2014).    
The preparation of killed vaccine includes inactivating the bacterins using heat or 
chemical like formalin. This will induce the responsible antigen in the host against the 
immune response (Ellis, 2001). To heighten the immune response, this killed vaccine 
can be prepared along with adjuvants. There are few commonly used killed vaccines 
such as aluminium hydroxide gel vaccines, bacterins, multiple (ME) vaccines and oil 
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adjuvant vaccines (OAV) against pasteurellosis. These vaccines have a variable 
duration to induce the hosts’ immunity (Chandrasekaran et al., 1994b and Verma and 
Jaiswal, 1997). Alum precipitated vaccine has been used widely in every part of the 
world and this vaccine provide immunity up to 6 months against P. multocida 
(Nikhiporova, 1958). In 2001, Shah et al. (2001) stated that the improve version of oil-
adjuvant HS from serotype B: 2.5 vaccine can provide protection towards serotype E: 
2.5. OAV happens to be high in viscosity which makes it crucial in administrating to the 
animal and form abscess at the injection site (Verma & Jaiwal, 1998).  
Multiple emulsion vaccines (MEV) were prepared by re-emulsifying OAV to an 
equal volume of Tween-80. This modification causes the vaccine to be administered 
easily and effectively protect the buffaloes against HS for up to 6 month period of time 
(Chandrasekaran et al., 1994). Newly formulated bacterin vaccine with toxoid provides 
high immune response in buffaloes. Longest protection up to 12 months against HS was 
given by OAV and double emulsion vaccine (Shah et al., 1997). Even though preparing 
bacterin vaccine is economical but this vaccine can only manage to provide immunity 
for short span of time which leads the occurrence of outbreaks frequently (Benkirane & 
De Alwis, 2002). In 2005, Sotoodehnia et al. (2005) stated preparation OAV with 
adjuvant Montanide ISA-70 may provide compromising protection in vaccinated calves.  
Development live vaccine P. multocida serotype B and other strain have been by 
using several chemicals and UV radiation shows that this vaccine can protect from HS 
infection in different types of farm animals (Verma & Jasiwal, 1998). One of a live 
vaccine was developed by growing P. multocida under iron-restricted has offered a high 
protective immunity in vaccinated animals (Srivastava, 1998). In Myanmar, fallow deer 
strain B: 3, 4 were used as live vaccine and gave protection to the cattle against P. 
multocida serotype B for one year after vaccination. On the other hand, passive 
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immunization against infection from P. multocida serotype E: 2, F: 3, 4 and A: 3, 4 was 
carried out in order to provide protection by using the collected serum from vaccinated 
cattle (Myint et al., 2005). Deletion of derivative aroA gene in P. multocida serotype B: 
2 will prevent the bacteria from growing in the host. The function of this gene is 
converting shikimic acid to chorismic acid during the synthesis of aromatic acids. This 
aromatic acid is accessing the bacteria to grow in the host whereby deleting this gene 
will help to inhibit the growth of bacteria (Tabatabaei et al., 2002). The same deletion of 
aroA gene in P. multocida p52 strain was carried out in different studies with 
replacement kanamycin resistance gene cassette and known as mutant P52Δaro. This 
mutant P52Δaro was being highly attenuated in mice and rabbit can be suitable live 
vaccine candidate in controlling HS in cattle and buffaloes since there were no 
pathological lesion were reported (Chaudhuri et al., 2012). The advantage of live 
vaccine is better in provoking cellular immunity (Haesebrouck et al., 2004; Hopkins et 
al., 1998).  
Antigenic part from P. multocida such as capsule, LPS, OMP or segment of cell wall 
can be used to develop acellular vaccine (Shivachandra et al., 2011). Development of 
acellular vaccine using ribosome and carrier protein from polysaccharides of P. 
multocida has no promising development (Verma & Jaiwal, 1998). Although, acellular 
vaccine appears to be safe in animals but, it provides less effective in immune response. 
Oil adjuvant and multiple emulsions have a significant importance in developing 
vaccine against HS among all the adjuvants. Combination of HS killed vaccine long 
with another pathogen has helped to reduce the vaccine doses and raise the immunity 
towards other infection (Verma & Jaiswal, 1998).  
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2.13.1 Molecular Approach Towards in HS Vaccine Prevention 
Recently, synthetic peptides, purified subunits, synthetic peptides, recombinant 
protein and chemical conjugation of polysaccharides have been used approached for 
vaccine production (Shivachandra et al., 2011). Subunit vaccine known is as second 
generation vaccine. This subunit vaccine consist immunogenic component of the 
pathogen to provoke immunity (Ahmad et al., 2014). Studies were carried out using 
capsular, one of an immunogenic component from P. multocida. This vaccine when 
given in higher dosage it was able to protect cattle against HS for one year (Maslog, 
1998). In 2008, Cho et al. stated combination polyvalent pasteurella vaccine together 
with adjuvant has the ability to provide immunity and create resistant against P. 
multocida infection. Development of subunit vaccine using OmpH protein, which was 
obtained from P. multocida showed a high antibody titer and able to proliferate T-cells 
in immunized animals (Kumar et al., 2011). Modification in OmpA by using heat 
develops cellular response against P. multocida (Confer & Ayalew, 2013).  
Recombinant protein produced by P. multocida triggered strong immunity (Hatfaludi 
et al., 2010). In order to produce this third generation vaccine, identification virulence 
and immunity genes from P. multocida is one of the important aspects that have been 
taken into account (Ahmad et al., 2014). The first recombinant protein vaccine which 
was successfully attempted was against rhinitis in pigs which was derived from P. 
multocida toxin (PMT) (Bording et al., 1994). Different approach have been encounter 
using recombinant vaccine by expressing the fimbrial protein P. multocida B: 2. It was 
found to provide significant protection and enhanced the stimulation of local and 
systemic immunities in goat when the vaccination was given via intranasal against HS 
(Yasin et al., 2011). Shivachandra et al. (2012) stated recombinant protein which was 
expressed using ptfA gene has the potential as recombinant vaccine candidate towards 
HS.  
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DNA vaccine or known as fourth generation vaccines that was produced from P. 
multocida B: 2 antigens might provide protective immunity against HS in cattle. The 
mechanism of this DNA vaccine was not clearly defined. Outer membrane protein 
(OMP) possesses a capability as DNA vaccine against HS (Singh et al., 2011). DNA 
vaccine appears to be efficient but limited by cost and technological default (Ahmad et 
al., 2014). 
Recombinant technology is reforming the shape of current vaccine development 
against P. multocida infection (Ahmad, 2014). Recombinant vaccine development can 
be a guidance to clarify the involvement of the associated genes in the pathogenesis of 
the disease (Wilkie et al., 2012).  
 
2.14 ABA392 Gene  
The recombinant clone ABA392 was derived from a P. multocida serotype B202, 
was constructed by shotgun cloning method (Salmah Ismail, 1997, 2004) using E. coli 
as host. Previously the sequenced recombinant plasmid (Salmah Ismail, 2000) harbours 
a sequence that encode for a virulence factor to P. multocida. Genomic DNA of isolated 
P. multocida serotype B202 was digested with restriction endonuclease Sau3A1 which 
generate restriction fragment of approximately 500 to 1000 bp. Then it was inserted at 
the BamHI site of the pUC18 vector. From 20 chosen recombinant plasmids, only three 
clones, namely ABA182, ABA292 and ABA392 are were found to be toxigenic in mice. 
Meanwhile, only one of the retrieved clone showed mortality in mice (Hussaini et al., 
2011). The ABA392 cloned has shown virulent characteristic when injected into mice 
as compared from the parental strain of PMB202. The size of recombinant plasmid 
clone of ABA392 was estimated at 3.2 kb and the DNA insert was determined as 921 bp 
(Accession No. DQ334273) using DNA sequencing analysis (Salmah Ismail, 2000,  
2004). Since the recombinant clone of ABA392 was capable to protect the host from 
22 
HS, it was then sub cloned into prokaryotic expression system (pQE32/M15). The 
potentials of the recombinant clone ABA392 as a vaccine candidate against 
hemorrhagic septicemia (HS) has been described and explored in mice model (Hussaini, 
2009; Salmah Ismail et al., 2010). They have shown a significant in which 90% of the 
mice vaccinated with the expressed clone (ABA392/pQE32) survived the challenge 
producing high antibody titer, whilst all unvaccinated mice died within 36 hours of the 
challenge. Meanwhile passive mouse protection test (PMPT) results showed that 83% of 
mice injected with hyper immune sera from vaccinated mice with ABA392/pQE32 were 
protected from the effects of P. multocida serotype B202. There were no survivors in 
unvaccinated group (Hussaini, 2009, 2011, 2012). 
 
 
23 
CHAPTER 3: MATERIALS AND METHODS 
(A)     Materials 
3.1 Bacteria Strain, Recombinant Clone ABA392 and Vector 
The bacteria strain that used in this study is P. multocida. The recombinant clone 
ABA392 was derived from parental strain P. multocida serotype B202 (PMB202). This 
clone was constructed by shotgun cloning method (Salmah Ismail, 1997; 2004) using E. 
coli as a host. Among the twenty recombinant plasmid previously sequenced (Salmah 
Ismail, 2000), ABA392 were found toxigenic to mice and thus harbors a sequence that 
code for a virulence factor for P. multocida. The expression vector that was used in this 
research is pET-30a with the size of 5422 bp. This expression vector was used to 
express the protein in E. coli system. Bacteria, ABA392 clone and vector were provided 
by Molecular Bacteriology and Toxicology Laboratory (MBT Lab) and stored in fridge 
-20ºC.  
 
3.2 Chemical and Reagents 
All the chemicals used were of Analar grade and highest grade available 
commercially. All chemical solution and molecular solution were purchased from 
Sigma Life, Liofilchem Diagnostic, Biorad, Thermo Scientific, Friendeman Schmidtt, 
Fermentas, Promega, and New England Biolabs.  
Luria-Bertani (LB) broth and agar powder were obtained from Liofilchem 
Diagnostic, Italy. Both Brain Heart Infusion (BHI) broth and agar powder were from 
BD, U.S.A meanwhile Acetone, acid sulfuric, sodium chloride, sodium hydroxide, tris-
EDTA were from Friendeman Schmidtt, Australia. Methanol, glycerol, acid 
hydrochloric, acid sulfuric,  glacial acetic acid and formalin were purchased from Fisher 
Scientific, U.S.A. Ethanol (absolute) were purchased from RCI Labscan, Australia.   
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Agarose powder and IPTG were purchased from Promega, U.S.A.  
Gene Ruler 1 kb plus DNA ladder, B-per Bacterial Protein Extraction Reagent 10X 
Tris-Borate-EDTA (TBE) electrophoresis buffer, Tween-20 and blood agar is from 
Thermo Scientific, U.S.A  
DNA purification and extraction kit is purchased from Macherey-Nagel, Germany.  
DNA ligation solution, Restriction Enzyme (RE), Supercoiled DNA ladder, 
Colorplus prestained protein ladder (#P7711S & P7712S) and 6X loading dye were 
from New England Biolabs (NEB), U.S.A. Gel red were from Biotium, California. 
Blueye prestained protein ladder from Gene Direx, Malaysia (Axon Scientific). 1kb plus 
DNA ladder and Escherichia coli BL21 (DE3) pLysS were from Invitrogen, U.S.A.  
Econotaq plus Green 2X mastermix is purchased from Lucigen, U.S.A. 
Anti-Mouse IgG, AP-linked antibody is purchased from Cell-Signaling, U.S.A 
Ampicillin, kanamycin, chloramphenicol, glycine, sodium phosphate, sodium 
carbonate, sodium salicylate, glycine, accustain harris hematoxylin solution, accustain 
Eosin Y solution, coomassie brilliant blue (CBB-250), 2-mercapthanol, skimmed milk 
powder and Bovine Serum Albumin (BSA) were from Sigma-Aldrich, U.S.A. 
Imidazole were purchased from Calbiochem, U.S.A.  
Penta Anti-HIS antibody was purchased from Qiagen, Germany.  
Anti-Mouse IgG, AP-linked antibody is purchased from Cell-Signaling, U.S.A 
IgG antibody (HRP) conjugate were obtained from Gene Tex, U.S.A 
Tetramethylbenzidine (TMB) substrate was purchased from Nacalai Tesque, Japan. 
Sodium doedecyl sulphate (SDS), 1.5M TRIS-HCL 8.8, 0.5M TRIS-HCL 6.8,  
Ammonium persulfate (APS), 30% Acrylamide, 2x sample buffer, and Bio-Rad DC 
protein assay and N’N’N’N’ Tetramethylethylenediaminie (TEMED), were from Bio-
Rad, USA.  
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Potassium chloride, sodium phosphate dibasic, sodium bicarbonate, dibasic sodium, 
turks solution and BCIP (5-Bromo-4-Chloro-3-indolyl phosphate) AP substrate were 
obtained from Merck, U.S.A meanwhile potassium dihydrogen phosphate were 
purchased from Riedel-De-Haen, Hannover, U.S.A. Monobasic sodium obtained from 
BDH, U.S.A.  
Xylene were purchased from R&M chemicals, Malaysia, paraffin from PC 
laboratory Reagent, U.S.A and DPX is obtained from Labchem, U.S.A.  
 
3.3 Apparatus 
The main machine involved were incubator, red line by binder, Germany.  Weighing 
balance was from A&D Company Limited, Japan. Volt power supply machine (PS-
300B) from AA Hoefer, U.S.A. Super bright UV trans-illuminator was from Vilber 
Lourmat, U.S.A.  Heating block was from Chemolab Supplies Sdn Bhd, Malaysia. 
Polymerase chain reaction  
(PCR) veriti 96 well thermal cycler, Sorvall ST 40R Centrifuge (4ºC) and  incubator 
shaker were obtained from Thermo Scientific, U.S.A, meanwhile gel doc (EZ) imager 
was from Bio-Rad, U.S.A. Mini-spin (eppendorf), Fisher Scientific, U.S.A. Thermolyne 
vortex maxi mix ii was from Labequip, Canada. Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis SDS-Page (Mini protean tetra system) was obtained 
from Bio-Rad, U.S.A. Bench top professional pH meter-BP3001 was from 
Transinstrument, Singapore. Magnetic stirrer-Cimarec 2 was from Thermolyne, Canada. 
Water bath-Grant was from sub-aqua, pro instrument, UK. Orbital shaker 110V was 
obtained from Komabiotech, Korea. Micropipettes, microcentrifuge tube and tips were 
all manufactured from Eppendorf, Germany. Others apparatus included are tips, tips 
container, petri dish, inoculate loops, ice box, floater, microcentrifuge tube rack, falcon 
tube, beaker and other glassware including glass and universal bottles.  
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3.4 Antibiotic Solutions 
Antibiotic stock solution for ampicillin (100mg/ml), kanamycin (30mg/ml) and 
Chloramphenicol (34mg/ml) were prepared as working concentrations and sterilized by 
filtration through sterile membrane filters (type PES, 0.22µm pore size) Millex-GP 
33mm Syringe Driven Filter Unit. The working solution were then dispensed in 1ml 
aliquots into sterile 1.5ml microcentrifuge tubes and stored at -20ºC.  The working 
solution was allowed to come to room temperature once removed from the cold and 
desired volume is then added to the sterile medium. 
3.5 Media and Broth 
The essential media and broth preparation used were Luria-Bertani (LB) and Brain 
Heart Infusion (BHI).  
3.5.1 LB Medium 
Standard LB medium powder : 21g 
Distilled water    : 1000ml 
The standard LB medium powder was dissolved and stirred using magnetic stirrer in 
1000ml distilled water. Each 10ml, 50ml or acquired of the mixture were aliquot in each 
universal bottle and conical flask and proceed to liquid autoclave at 121ºC for 1 to 2 
hours before it is used.  
3.5.2 LB Agar   
Standard LB agar powder  : 37.0g 
Distilled water    : 1000ml 
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3.5.3 LB Agar with Ampicillin 
Standard LB agar powder  : 37.0g 
Ampicillin    : 100µg/ml 
Distilled water    : 1000ml 
3.5.4 LB Agar with Kanamycin 
Standard LB agar powder  : 37.0g 
Kanamycin    : 30µg/ml 
Distilled water    : 1000ml  
3.5.5 LB Agar with Chloramphenicol 
Standard LB agar powder  : 37.0g 
Chloramphenicol   : 34µg/ml 
Distilled water    : 1000ml 
3.5.6 LB Agar with Kanamycin/ Chloramphenicol 
Standard LB agar powder  : 37.0g 
Kanamycin    : 30µg/ml 
Chloramphenicol   : 34µg/ml 
Distilled water   : 1000ml 
3.5.7 LB Agar with IPTG 
Standard LB agar powder  : 37.0g 
IPTG    : 0.1M 
Distilled water    : 1000ml 
3.5.8 LB Agar with Kanamycin/Chloramphenicol/IPTG 
Standard LB agar powder  : 37.0g 
Kanamycin    : 30µg/ml 
Chloramphenicol   : 34µg/ml 
IPTG    : 0.1M 
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Distilled water    : 1000ml 
The standard LB agar powder was dissolved and stirred using magnetic stirrer in 
1000ml distilled water. The solution was cooled down to 50ºC. Once cooled down, 
ampicillin (100µg/ml), kanamycin (30µg/ml), chloramphenicol (34µg/ml) and IPTG 
(0.1M) were then added according desired concentration then the agar solution was 
poured into petri dishes with ~20ml each plate and cooled down. Once the agar 
solidified, the LB agar plates were sealed using parafilm and stored at 4ºC.  
3.5.9 Luria-Bertani (LB) Slant 
The preparation of LB agar slant was similar as preparation LB agar plate but the 
solution was poured in universal bottles and added with the appropriate concentration of 
ampicillin (100µg/ml), kanamycin (30µg/ml), chloramphenicol (34µg/ml) and slanted 
one side. The bottles were slanted overnight in purpose for the agar to solidify in slope 
form.  
3.5.10 Brain Heart Infusion (BHI) Medium 
Standard BHI medium powder : 32.0g 
Distilled water    : 1000ml 
The BHI medium powder was dissolved and stirred using magnetic stirrer in 1000ml 
distilled water. Each 10ml, 50ml or acquired of the mixture were aliquot in each 
universal bottle and conical flask and proceed to liquid autoclave at 121ºC for 1 to 2 
hours before it is used.  
3.5.11 BHI Media 
Standard BHI agar powder : 52.0g 
Distilled water    : 1000ml 
The standard BHI agar powder was dissolved respectively and stirred using magnetic 
stirrer in 500ml distilled water. The solution was cooled down to 50ºC. The agar 
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solution was poured into petri dishes with ~20ml each plate and cooled down. Once the 
agar solidified, the BHI agar plates were sealed using parafilm and stored at 4ºC.  
3.5.12 Blood Agar 
Blood agar was purchased commercially and stores at 4ºC prior to use 
3.6 DNA Purification and Extraction kit 
There were two types of kits have been used in this research, plasmid DNA 
purification (Section 3.20) and PCR clean-up Gel extraction (Section 3.24).  
3.6.1 NucleoSpin® Plasmid 
This kit was used to purify gene and vector of interest, ABA392 and pET-30a 
respectively.  
Resuspension Buffer A1    : 15ml 
Lysis Buffer A2     : 15ml 
Neutralization Buffer A3    : 20ml 
Wash Buffer AW     : 30ml 
Wash Buffer A4     : 2 X 6ml 
Elution Buffer AE     : 15ml 
RNase A      : 6mg 
NucleoSpin Plasmid Columns Tubes (white rings) : 50pc 
Collection Tubes (2ml)     : 50pc 
3.6.1.1 Buffer A1 
1ml of Buffer A1 was added to RNase A vial and vortex. All the resulting solution 
was transferred into the Buffer A1 bottle and mixed thoroughly. Buffer A1 was stored at 
4ºC. 
3.6.1.2 Buffer A4 
24mL of 96% ethanol was added into Buffer A4 and mixed thoroughly.  
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3.6.2 NucleoSpin® Gel and PCR Clean Up 
This kit was use for DNA extraction of ABA392 gene and pET-30Aa from the 
agarose gel.  
Binding Buffer NTI      : 2x25ml 
Wash Buffer NT3 (Concentrate)      : 20ml 
Elution Buffer NE       : 15ml 
NucleoSpin Gel and PCR Clean-up Columns (Yellow rings) : 50pc 
Collection Tubes (2ml)       : 50pc 
3.6.2.1 Buffer NT3 
80ml of 96% Ethanol was added into wash buffer NT3 and mixed thoroughly. 
3.7 Agarose Gel Electrophoresis 
The materials that need to prepare agarose gel electrophoresis was agarose powder, 
Tris/Borate/EDTA (TBE) buffer and gel red for staining purpose. The amount of 
agarose powder depends on the percentage agarose gel that used. The percentage of gel 
that were used in this research is 0.7% and 1%. This agarose powder was stored at room 
temperature (25 ± 2ºC). 
3.7.1 Agarose Gel, 0.7% 
The mass of agarose powder that need to prepare is determined by 0.7% w/x of 1X 
TBE buffer volume. This concentration shows better separation for PCR samples and 
0.7% agarose gel is usually prepared in total amount of 50ml. The standard amount used 
that for preparing the gel as below.  
Agarose powder   : 0.35g  
TBE buffer, 1X   : 50ml 
To prepare 7% agarose gel, 0.35g of the agarose powder was weigh by using 
analytical balance and mixed into 50ml of 1X TBE buffer in a 100ml Scott bottle. This 
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solution is mixed well and boiled in microwave oven for 1 minute at medium 
temperature with loosen cap. Once the solution was dissolved, the solution will be 
cooled down to 50ºC and poured into gel loader. A well comb is inserted immediately 
after the pouring. It was important to make sure there is no bubble. The gel was cooled 
for 20 to 30 minutes for solidification. The well comb was removed once the gel has 
solidified for electrophoresis run.  
3.7.2  Agarose Gel, 1% 
The mass of agarose gel powder used was 1% w/v of 1X TBE. This concentration 
was used for plasmid samples. The amount that needs to prepare 1% agarose gel is as 
below: 
Agarose powder  : 0.5g 
TBE buffer, 1X  : 50ml 
1% agarose gel was prepared as described above in Section 3.7.1.  
3.7.3 Tris/Borate/EDTA (TBE) Buffer, 1X 
TBE (10X) buffer were purchased commercially and stored at room temperature (25 
± 2ºC). 1X TBE buffer was diluted from 10X TBE which consist of 89mM Tris, 89mM 
Boric Acid and 2mM EDTA to required volume and stored at room temperature (25 ± 
2ºC). 
3.7.4  Loading Dye and DNA Marker 
The loading dye that was used is gel loading dye purple (6x) and volume is about 1µl 
(1 volume of the dye solution 5 volumes of the DNA sample). Three types of DNA 
marker have been used in this research which is 1 kb Plus DNA ladder (0.1µg/µL), 
Gene ruler 1 kb plus DNA ladder (0.5µg/µL) and supercoiled DNA ladder (500µg/ml). 
The volume that was used is about 5µl. Both loading dye and DNA ladder were stored 
at -20ºC. 
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3.7.5 Gel Red Staining (Post Staining) 
Once the gel electrophoresis is done, gel was stained in gel red staining. The Gel 
RedTM 10000X stock solution was diluted 3,300 fold to make a 3X staining solution in 
distilled water. The staining preparation as below:  
Gel red    : 30µl 
Sterile distilled water  : 100ml 
30µl of gel red was mixed with 100ml sterile water in a clean container and sealed 
with aluminum foil since it is light sensitivity. Gel was stained for 5 to 10 minutes and 
bands were viewed using UV trans-illuminator. This gel red was stored at 4ºC.   
3.8 DNA Cloning 
3.8.1 Restriction Endonuclease (RE) 
There are two types of RE were used, HindIII-HF and BamHI-HF. These enzyme 
were used together with restriction enzyme (RE) buffer (10X) during digestion process. 
Below are the RE site sequence for both enzymes:  
(i) HindIII-HF: AAGCTT 
(ii) BamHI-HF: GGATCC 
Both RE and RE buffer (10X) were stored at -20º. 
3.8.2 DNA Ligation Solutions 
The DNA ligation solution used was T4 DNA Ligase Reaction Buffer (10X) 
consists of (Tris-HCl, MgCl2, ATP, and DTT) and T4 DNA Ligase with 10mm ATP. 
All these solutions were stored at -20ºC. 
3.9 Transformation 
3.9.1 Types of Cells 
The competent cells that were used were Escherichia coli (E. coli) and the strain was 
BL21 (DE3) pLysS. This strain was used during pET-30a transformation.  
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3.9.2 Transformation Buffer, 0.1M 
The mass of calcium chloride dehydrate to prepare transformation buffer was:  
Calcium chloride, CaCl2 (Mw: 110.98g/mol)  : 1.1g 
Distilled water      : 100ml 
This solution was autoclaved and stored at 4ºC. This solution was used during 
preparation of competent cells (Section 3.26.1).  
3.10 Polymerase Chain Reaction (PCR) 
3.10.1 Mastermix 
The total volume of PCR mix that has been used was 25µl. Econotaq Plus Green 2X 
mastermix was used which consists of 0.1units/µl of Econotaq DNA polymerase, 
reaction buffer (pH 9.0), 400µm dATP, 400µm dGTP, 400µm dCTP, 400µm dTTP, 
3mm MgCl2, PCR enhancer/stabilizer and blue/yellow tracking dyes. The composition 
of PCR mix will be described in the method Section 3.27. This mastermix was stored at 
-20ºC.  
3.10.2 Primer 
The primer was synthesized from MyTACG Bioscience Enterprise. This primer was 
designed based on ABA392 gene which derived from parental strain P. multocida 202. 
This primer was use during PCR amplification, colony screening and gene insert 
analysis. The DNA sequence below shows the designed primers:  
(i)  F- 5’ATGAGTCTTTTGTTCTGTCGCTTG’3  
(ii) R- 5'CTAGCGGCGGTGGAAACCCGCCAT'3 
3.11 Protein Expression of ABA392/pET-30a Recombinant Clone  
3.11.1 Isopropyl-β-D-thiogalactopyranoside (IPTG), 0.1M 
The mass of IPTG that required is as below:  
IPTG, C9H18O5S (MW: 238.298g·mol-1)  : 0.24g 
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Sterile dH20      : 10ml 
The solution is sterilized by filtration through a 0.22µm membrane and stored at -
20ºC. 
3.11.2  Phosphate Buffer Saline (PBS), 10X 
This solution was purchased commercially and stored at room temperature. 10X PBS 
is diluted to 1X concentration prior to use. 
3.11.3 Protein Lysis Buffer 
The protein lysis buffer that was used in this research is B-PER® Bacterial Protein 
Extraction Reagent.  
3.11.4 Lysozyme and DNAase 1 
This solution was purchased commercially and stored at -20ºC.  
3.12 Purification of 6xHis-tagged Protein using Dynabeads 
3.12.1 Dynabeads His-Tag Isolation and Pulldown 
The expressed His-tag protein from recombinant clone ABA392/pET-30a was 
purified using Dynabeads His-Tag Isolation and Pulldown and it was bought 
commercially. 
3.12.2 Binding/Wash Buffer (50ml), 2X 
To prepare Binding/Wash buffer, 2X:  
Sodium Phosphate, NaH2PO4 (MW: 120g/mol), 100mM, pH 8   : 0.6g 
Sodium Chloride, NaCl (MW: 58.44g/mol), 600mM   : 1.7532g 
Tween®-20, 0.02%        : 10µl 
HCl/NaOH         : Adjust pH  
This solution was dissolved in 50ml distilled water and pH was adjusted to 8 by 
using NaOH and stored at 4ºC. 2X Binding/Wash buffer was diluted to 1X 
concentration prior to usage. 
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3.12.3 His Elution Buffer (50ml) 
To prepare His Elution Buffer:  
Imidazole, C3H4N2 (MW: 68.077g/mol), 300mM   : 1.021g 
Sodium Phosphate NaH2PO4 (MW: 120g/mol), 50mM, pH 8 : 0.3g 
Sodium Chloride, NaCl (MW: 58.44g/mol), 50mM  : 0.8766g 
Tween®-20, 0.01%       : 5µl 
HCl/NaOH        : Adjust pH  
This solution was dissolved in 50ml distilled water and pH was adjusted to 8 by 
using NaOH and stored at 4ºC. 
3.13 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
3.13.1 Acrylamide/Bis Solution, 30% 
This solution was purchased commercially and stored at room temperature. 50ml of 
this is aliquot in falcon tube prior to use and stored at 4ºC. 
3.13.2 Resolving Gel Buffer, 1.5M Tris-HCl, pH 8 
This solution was purchased commercially and stored at room temperature. 50ml of 
this solution was aliquot in falcon tube prior to use and stored at 4ºC. 
3.13.3 Stacking Gel Buffer, 0.5M Tris-HCl, pH 6.8 
This solution was purchased commercially and stored at room temperature (25 ± 
2ºC). 50ml of this solution was aliquot in falcon tube prior to use and stored at 4ºC. 
3.13.4 Sodium Dodecyl Sulfate (SDS), 10% 
The mass of 10% (w/v) SDS that was needed as below:  
SDS, NaC12H25SO4 (MW: 288.372g/mol)  : 5.0g  
Distilled water     : 50.0ml 
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The solution was mixed and filtered and stored at room temperature (25 ± 2ºC).  
3.13.5 Ammonium persulphate (APS), 10% 
APS was used as polymerizing agent in gel. The mass of ammonium persulphate that 
needed was:  
 Ammonium persulphate, (NH4)2S2O8 (MW: 228.18g/mol) : 0.1g 
 Distilled water      : 1.0ml 
 This solution was prepared freshly prior to usage.  
3.13.6 N’N’N’N’-Tetramethylethylenediamine (TEMED 
This solution was purchased commercially and stored at 4ºC. 
3.13.7 Running Buffer (25mM Tris, 192mM Glycine, 0, 1% SDS)  
Tris Base, C4H11NO3 (MW: 121.14g/mol)   : 3.03g 
Glycine, C2H5NO2 (MW: 75.0g/mol)    : 14.4g 
SDS, NaC12H25SO4 (MW: 288.372g/mol)    : 1.0g 
The solution was dissolved in 1000ml distilled water and stored at room temperature 
(25 ± 2ºC).  
3.13.8 Laemli Sample buffer, 2X 
This solution was purchased commercially and stored at room temperature (25 ± 
2ºC). 2X Laemli sample buffer consist of 68.5mM Tris-HCl, pH 6.8, 2.1% SDS, 26.3% 
(w/v) glycerol and 0.01% bromophenol blue. This solution was diluted to 1:20 with 2-
mercapthenol prior to usage. 
3.13.9 Protein Ladder 
The protein ladder was colorplus prestained (#P7711S & P7712S) and blueye 
prestained protein ladder. 
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3.13.10 Colloidal Coomassie Staining (0.08% Coomassie Brilliant Blue (CBB) 
G250, 1.6% Ortho-phosphoric Acid, 8% Ammonium sulfate, 20% 
Methanol) 
Ortho-phosphoric Acid, H3PO4 (MW: 98.00g/mol) : 16ml 
Ammonium Sulfate, (NH4)2SO4 (MW: 132.14g/mol)  : 80g 
CBB 250, 5%      : 16ml 
Methanol, CH4O (MW: 32.04)     : 200ml 
16ml Ortho-phosphoric Acid was mix into 768ml of distilled water. 80g of 
ammonium sulfate and 16ml of 5% CBB G250 were then added into the previous 
mixture. Slowly 200ml methanol was added to the solution to give final volume of 
1000ml (Neuhoff, et al, 1985). 
3.13.11 De-staining Solution 
Distilled Water  : 100ml 
The de-staining process was done on the gel until the background of the gel 
transparent was appeared (Neuhoff, et al, 1985).  
3.13.12 Quantification of His-tag Protein  
The Bio-Rad DC protein assay were bought commercially and stored at room 
temperature (25 ± 2ºC).  
3.13.12.1 Bovine Serum Albumin (BSA)  
Bovine serum albumin was purchased commercially and prepared 10mg/ml as stock 
solution. The stock solution was stored at -20ºC. 
3.14 Western Blotting 
3.14.1 Blotting Buffer (Transfer Buffer), 1X pH 8.3 
Tris Base, C4H11NO3 (MW: 121.14g/mol) : 3.03g 
Glycine, C2H5NO2 (MW: 75.07g/mol)  : 14.4g 
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Methanol, CH3OH (MW 32.04g/mol)  : 200ml 
Naoh/HCl      : Adjust pH  
Distilled water      : 1000ml 
 3.03g of tris base and 14.4g glycine were mix into 200ml methanol. Once 
dissolved, distilled water was top up till 1000ml and pH was adjusted to 8.3. The 
solution was stored at room temperature (25 ± 2ºC).  
3.14.2 Blocking Buffer, 5% (w/v) 
Skimmed milk powder     : 0.5g 
TBS, 1X      : up to 10ml 
0.5g of skimmed milk was mix with 1X TBS up to 10ml. This solution was freshly 
prepared prior to usage. 
3.14.3 Tris-Borate Saline (TBS), 5X, pH 7.5 
Tris Base, C4H11NO3 (MW: 121.14g/mol) : 12.11g 
Sodium chloride, NaCl (MW: 58.44g/mol) : 48.85g 
Distilled water      : 1000ml 
HCL/NaOH     : Adjust pH 
12.11g tris base and 48.85g NaCl were mixed into 1000ml until it dissolved. pH was  
adjusted to 7.5. The solution was stored at room temperature (25 ± 2ºC). This solution 
will be diluted to 1X prior to usage.   
3.14.4 TBS –Tween 20 (TBST), 0.2% 
TBS, 1X (Section 3.14.1)    : 1000ml 
Tween-20      : 2ml 
This solution was mixed and stored at room temperature (25 ± 2ºC). This solution 
served as washing buffer.  
3.14.5 Skimmed milk, 2.5% (w/v) 
Skim milk powder     : 0.5g 
39 
TBS, 1X       : up to 20ml  
0.5g of skimmed milk was mixed with 1X TBS up to 20ml. This solution was freshly 
prepared prior to usage.  
3.14.6 BCIP (5-Bromo-4-Chloro-3-indolyl phosphate) AP Substrate 
This solution was purchased commercially and stored at 4ºC. 
3.14.7 Primary and Secondary Antibody 
Penta Anti-His antibody and IgG, AP-linked antibody was bought commercially and 
stored at 4ºC.  
3.15 Histopathology Analysis 
3.15.1 Mono Basic Phosphate, 0.1M 
Mono Basic Phosphate NaH2PO4 (MW: 156g/mol) : 15.6g 
Distilled Water      : 1000ml 
15.6g was dissolved in 1000ml distilled water to make 0.1M solution. This stock 
solution was stored at room temperature (25ºC ± 2ºC). 
3.15.2 Dibasic Phosphate, 0.1M 
Dibasic Phosphate Na2HPO4.2H2O (MW: 178g/mol)  :17.8g 
Distilled Water      : 1000ml  
1000ml of distilled water was filled in beaker before stirring. Small amount of 
dibasic phosphate was added and make sure it was dissolved completely. The remaining 
dibasic phosphate was added gradually until the whole amount is dissolved. This stock 
solution is stored in room temperature (25 ± 2ºC). 
3.15.3 Phosphate Buffer, 0.1M 
Mono Basic Phosphate, NaH2PO4, 0.1M (Section 3.15.1)  : 500ml 
Di Basic Phosphate, Na2HPO4.2H2O, 0.1M (Section 3.15.2)  : Adjust pH 
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500ml of 0.1M Mono Basic Phosphate was added into Scott bottles. pH was adjusted 
using 0.1M Di Basic Phosphate until pH reach 7.3. This solution was stored at room 
temperature (25 ± 2ºC). 
3.15.4 Neutral Buffer Formalin, 10%, pH 7.3 
Phosphate Buffer, 0.1M (see Section 3.15.3) : 500ml 
Formalin (37%)     : 100ml 
Distilled Water     : 400ml 
All the solution is were added together to obtain 1000ml of 10% buffered formalin. 
This solution was stored at room temperature (25 ± 2ºC). 
3.15.5 Mayer’s Albumin 
Fresh egg white      : 50ml 
Glycerol       : 50ml  
Sodium Salicylate, C7H5NaO3 (MW: 160.11g/mol)  : 1g 
All the solution were added together and stored at 4ºC.   
3.15.6 Histopathology Staining (Hematoxylin and Eosin staining (H&E) )  
3.15.6.1 Harris Hematoxylin 
This solution was purchased commercially and stored at room temperature (25 ± 
2ºC). Harris hematoxylin was filtered and 50ml of the solution was aliquot in falcon 
tube prior to usage.  
3.15.6.2 Eosin Y 
Eosin Y       : 100ml  
Glacial Acetic Acid, CH3COOH (MW: 60.05g/mol) : 0.5ml 
Acidified Eosin Y solution, Aqueous was prepared by slowly adding 0.5ml of glacial 
acetic acid per 100mL. 50ml of Eosin Y was aliquot in falcon tube and was stored at 
room temperature (25 ± 2ºC).  
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3.16 Enzyme-Linked Immunosorbent Assay (ELISA)  
3.16.1 Coating Buffer, pH 9.6 
Sodium carbonate, Na2CO3 (MW: 105.99g/mol)  : 1.06g 
Sodium Bicarbonate, NaHCO3 (MW: 84.00g/mol) : 0.84g 
Naoh/HCl       : Adjust pH  
Distilled water       : 200ml 
3.16.2 Coating Antigen 
About 30 uniform single colonies of P. multocida B: 2 which grown on blood agar 
was inoculated into 200ml of sterile BHI broth and incubated at 37ºC for 16 hours. The 
overnight broth containing bacteria was centrifuge and the supernatant was discarded. 
The pellet was washed with sterile PBS and centrifuge at 4000rpm for 30minutes 
respectively. The pellet was resuspended with 200ml of coating buffer (see Section 
3.16.1) and boiled at 97ºC for 20 minutes. The inoculum was left to cool and was 
allocated into 1.5ml microcentrifuge tubes. The allocated inoculum was stored at -20ºc 
till prior to usage.  
3.16.3 Washing Buffer (PBS-Tween 20), pH 7.4 
Sodium chloride, NaCL (MW: 58.44g/mol)    : 8.0g 
Potassium dihydrogen phosphate, KH2PO4 (MW: 136.09g/mol)  : 0.2g 
Sodium phosphate dibasic, HNa2O4P.2H2O (MW: 141.96g/mol)  : 2.9g 
Potassium chloride, KCl (MW: 74.55g/mol)    : 0.2 
Tween 20(added after autoclave)      : 0.5ml  
Distilled Water        : 1000ml 
HCl/NaOH         : adjust pH 
 This solution was dissolved in 1000ml distilled water and autoclaved. Tween 20 
was added later and solution pH was adjusted to 7.4 and store at room temperature (25 ± 
2ºC) till prior to usage.  
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3.16.4 Blocking Buffer (PBS-Tween 20-BSA), pH7.4 
Sodium chloride, NaCL (58.44g/mol)    : 8.0g 
Potassium dihydrogen phosphate, KH2PO4 (136.09g/mol) : 0.2g 
Sodium phosphate dibasic, HNa2O4P.2H2O (141.96g/mol) : 2.9g 
Potassium chloride, KCl (MW: 74.55g/mol)   : 0.2g 
Tween 20 (added after autoclave)     : 0.5ml 
Bovine Serum Albumin (BSA)      : 10.0g 
Distilled Water        : 1000ml 
HCl/NaOH        : adjust pH 
 This solution was dissolved in 1000ml distilled water and autoclaved. Tween 20 
and BSA were added later and solution pH was adjusted to 7.4 and store at 4ºC till prior 
to usage.  
3.16.5 Tetramethylbenzidine (TMB) 
This solution was purchased commercially stored at 4ºC.  
3.16.6 Stopping Buffer 
Acid sulphuric, H2SO4 (MW: 98.00g/mol) : 29.36ml 
Distilled Water     : 200ml 
This solution was dissolved in 1000ml distilled water and stored at 4ºC till prior to 
use. 
3.16.7 Secondary Antibody   
IgG antibody (HRP) conjugate was purchased commercially and stored at 4ºC.  
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(B)     Method 
3.17 Washing Procedures 
All the glassware and wash ware items were soaked in teepol solution overnight and 
washed thoroughly under running tap water and lastly rinsed with distilled water. All 
washed items then were allowed to dry by heat drying at 60ºC in oven.  
3.18 Sterilization 
Throughout this research conducted, sterile condition was applied. All the media, 
reagents, chemical, distilled water and plastic disposable such as pipettes, tips, 
microcentrifuge tube, polymerase chain reaction (PCR) tube were sterilized in an 
automated autoclave 121ºC (50psi) for approximately 45 minutes. Glassware such as 
conical flask, beakers, measuring cylinders, bottles (universal and bijou) was sterilized 
in hot air oven at 180ºC for 2 hours. Antibiotic and other solution were sterilized using 
Millipore filter.  
3.19 Storage and Maintenance of Bacterial Culture 
All the overnight cultures were mixed with equal volume of 60% sterile glycerol and 
stored at -20ºC. Working stock culture were sub-cultured every two week and 
maintained on slant agar for period of 3 to 5 months.  
3.20 Purification of ABA392/pUC57 using NucleoSpin® Plasmid 
A single grown colony from LB agar with ampicillin 100µg (Section 3.5.3) of 
ABA392/pUC57 was grown in LB broth (Section 3.5.1) which contain ampicillin with 
final concentration of (100µg) at overnight in 37ºC shaking incubator. Before 
proceeding with purification step, 600µl was aliquot in different microcentrifuge tube 
for glycerol stock preparation as mentioned in Section 3.19. 1 to 5ml of overnight 
saturated LB culture was harvested in a standard microcentrifuge for 1 minute at 11,000 
x g. The supernatant was discarded and liquid was removed as much as possible. To 
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lysis the cell, the harvested cell was suspended in 250µl buffer A1 completely by 
pipetting up and down until there were no clumps remained. 250µl buffer A2 was added 
and mixed gently by inverting the tube 6 to 8 times and incubated at room temperature 
to 5 min or until the lysate appears clear. After 5 minutes, 350µl buffer A3 was added 
and mixed thoroughly up to 6 to 8 times and centrifuge for 10 minutes at 11,000 x g.  
Meanwhile, a nucleospin plasmid column was placed in a collection tube (2ml) to bind 
the DNA. Once centrifugation was completed, the 750µl of the supernatant was pipette 
onto the column and centrifuge for 1 min at 11, 000 x g.  The flow through was 
discarded and the nucleospin plasmid column was placed back into the collection tube. 
To wash the cells, buffer AW was preheated to 50ºC and 500µl was added into the 
column and centrifuge for 1 min at 11,000 x g and followed with washing step with 
buffer A4. 600µl of buffer A4 was added and centrifuged for 1 min. The flow through 
was discard and nucleospin plasmid column was placed back into the empty collection 
tube. To dry the silica membrane, the column was centrifuge again for 2 min at 11,000 x 
g and the collection tube was discarded. To elute the DNA, the nucleospin plasmid 
column was placed on clean 1.5ml microcentrifuge tube and 50µl buffer AE was added 
and allowed to incubate at room temperature for 1 minute and centrifuge for 1 min at 
11,000 x g. All the purified DNA sample was stored at -20ºC to prior use. 
3.21 Isolation and Purification of pET-30a 
A single grown colony of pET-30a from LB agar with kanamycin 30µg (Section 
3.5.4) was grown in LB broth (Section 3.5.1) which contain kanamycin with final 
concentration of 30µg at overnight in 37ºC shaking incubator. Since pET-30a is a low 
copy plasmid, 1 up to 10mL of overnight saturated LB culture was harvested. Before 
proceeding with purification step, 600µl is aliquot in different microcentrifuge tube for 
glycerol stock preparation as Section 3.19 and followed by purification step as Section 
3.20. All the purified DNA was stored at -20ºC to prior use. 
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3.22 Agarose Gel Electrophoresis for Purify ABA392/pUC57 and pET30a 
The purify ABA392/pUC57 and pET-30a were analyzed by 1% gel electrophoresis 
which prepared as section 3.7.2. 4µl of purified DNA sample was mixed with 1µl 
loading dye and pipetted into the gel wells. 5µl of supercoiled ladder was mixed up with 
1µl loading dye was used as the size reference. The gel was run for at 70V for 60 to 75 
minutes. The detection of the band was made by viewing the gel under UV light.  
3.23 Restriction Endonuclease Digestion of ABA392 Gene and pET-30a 
Restriction endonuclease digestion was carried out to obtain the insert (ABA392) and 
vector (pET-30a) and to re-confirm the fragment size. The insert was prepared by 
treating the ABA392 with restriction digestion enzyme HindIII-HF and BamHI-HF. The 
ABA392 gene was digested using the ingredients and condition as below (Table 3.1). 
The same protocol was applied for pET-30a: 
Table 3.1: Restriction Enzyme (RE) digestion profile of ABA392 gene and pET-30a 
vector 
Solutions Volume (µl) 
Cut Smart® Buffer 2.5µl 
HindIII-HF  (Restriction enzyme) 1.0µl 
BamHI-HF (Restriction enzyme) 1.0µl 
DNA 20.5µl 
Total 25.0µl 
 
The solution was mixed and was incubated at 37ºC for 2 hours. The digestion was 
confirmed by agarose gel electrophoresis to identify the size of the ABA392 gene and 
pET-30a vector.  
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3.24 Gel Extraction of ABA392 gene and pET-30a Vector using NucleoSpin® 
Gel and PCR Clean Up 
The DNA fragment with the band size was excised from the agarose using a clean, 
sharp scalpel  under long wave UV light for short time. Appropriate UV precautions 
were taken. The gel slice was weighed in a clean microcentrifuge tube. Each 100mg of 
agarose gel <2%, 200µl buffer NTI was added. The tube was incubated at 50ºC for 5 to 
10 minutes (until the gel slice completely dissolved) and sample was vortex briefly 
every 2-3 minutes during the incubation to dissolve the gel. To bind the DNA, a 
nucleospin gel and PCR Clean-up Column was placed in collection tube (2mL) and all 
dissolved sample was loaded. The tube was centrifuged for 1 min at 11, 000 x g. The 
flow through was discarded and the column was placed back into the collection tube. To 
wash the silica membrane, 700µl buffer NT3 was added into the nucleospin gel and 
PCR Clean-up Column and centrifuge for 1 min at 11,000 x g. The flow through was 
discarded and the column was placed back into the collection tube. This washing step 
was repeated again to minimize chatropic salt carry over. The column was centrifuged 
for 1 min at 11, 000 x g to remove buffer NT3. To elute the DNA, the nucleospin gel 
and PCR Clean-up Column was placed on microcentrifuge tube. 30µl buffer NE was 
added and incubated for 1 min at room temperature. The column was centrifuge for 1 
min at 11, 000 x g. The extracted gel was analyzed by 1% gel electrophoresis which was 
prepared as section 3.7.2. 4µl of purified DNA sample was mixed with 1µl loading dye 
and pipetted into the gel wells. 3µl of DNA ladder was mixed up with 1µl loading dye 
was used as the size reference. The gel was run for at 70V for 60 to 75 minutes. The 
detection of the band was made by viewing the gel under UV light. 
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3.25 Ligation by NEB T4 DNA Ligase Reaction Buffer  
The ligation of digested insert (ABA392) and vector pET-30a was carried out using T4 
ligase under standard condition (Sambrook et al., 1989). The ligation mixture 
ingredients and conditions were as follow (Table 3.2):  
Table 3.2: Ligation Profile of ABA392 gene and pET-30a Vector 
 
Solutions Volume ( µl) 
Cut Smart 10x T4 DNA ligase Buffer 
mart® Buffer 
2µl 
Vector (digested pET-30a with HindIII-
HF and BamHI-HF) 
4 µl 
Insert (digested ABA392 with HindIII-
HF and BamHI-HF) 
13µl 
T4 DNA ligase 1µl 
Total 20µl 
 
The solutions were mixed and incubated 16 hours at 16ºC before being transformed 
into E. coli as described in Section 3.26.2 
3.26 Transformation of Plasmid DNA into Host Cell 
3.26.1 Preparation of Competent Cells 
Stock culture of E. coli BL21 (DE3) pLysS was streaked out on Luria-Bertani (LB) 
agar with chloramphenicol plate (Section 3.5.5) and was incubated at 37ºC overnight. A 
single colony was then inoculated into 10ml LB broth with chloramphenicol added and 
incubated overnight. 1ml of the overnight culture was then added into 50ml prewarmed 
LB flask and was shaken at 220 rpm for 2 to 3 hours until the OD600 reach 0.5 at 600nm. 
The culture was then cooled on ice for 10 minutes and centrifuged at 3500 rpm at 4ºC 
for 1 hour. The supernatant was discarded and the pellet was resuspended in 5ml chilled 
0.1M transformation buffer (Section 3.9.2) and chilled on ice for 20 minutes. The 
competent of the cells was found to be its maximum when kept overnight.  
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3.26.2 Transformation of ABA392/pET-30a into E. coli BL21 D3 pLysS 
5µl of the ligation reaction from Section 3.25 was transformed into 100µl of E. coli 
BL21 (DE3) pLysS competent cells in the 1.5ml microcentrifuge tube. The tube with 
the mixture was placed on the ice for 30 minutes and followed by placing it on the 
heating block at 42º for 2 minutes. The tube then chilled on ice for 5 minutes. 0.9ml of 
LB broth was added into the mixture and mixed well. The mixture was incubates at 
37ºC in a shaking incubator for 90 minutes. After the incubation, the tube was 
centrifuged for 1 min at 13,000 x g and the supernatant was discarded. 50µl LB broth 
was added and mixed well with the remaining pellet and spread on LB agar with 
kanamycin/chloramphenicol plate (Section 3.5.6) for screening. Only transformed 
cultures survive on this plate as they contain the kanamycin/chloramphenicol resistance 
gene.  
The transformed E. coli BL21 (DE3) pLysS were incubated at 37ºC overnight. The 
transformed colonies were analyzed by using direct colony PCR as described in Section 
3.27. Positive colonies (colonies carrying the vector) were grown up in 
kanamycin/chloramphenicol broth to amplify the construct and for glycerol storage 
(Section 3.1). 
3.27 Colony Library and PCR Colony Screening 
In this PCR colony screening, the colonies were screened based on the resistance 
towards kanamycin/chloramphenicol. Before proceeding with PCR colony screening, 
grids were drawn in a new LB agar with kanamycin/chloramphenicol plate. Each colony 
from the overnight transformation plate were picked using clean and sterilized toothpick 
and touched with the specific grids of the library plate. The plate was incubated 
overnight at 37º C. PCR was performed directly without DNA purification. Colony was 
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picked from each grid using inoculate loop from overnight plate to detect the positive 
colonies that carrying the insert. 
Isolated colonies were picked and mixed by pipetting with the PCR solution as in the 
table 3.3: 
Table 3.3: PCR mastermix  
 
Solutions 25µl Reaction Final 
concentration 
Econotaq Plus Green 2x mastermix 
(Section 3.10.1) 
12.5µl 1X 
Forward primer (Section 3.10.2) 0.25µl (pmol/µl) (1µm) 
Reverse primer (Section 3.10.2) 0.25µl (pmol/µl) (1µm) 
DNA Template 1.0µl  
Water nuclease free 11.0µl  
 
All constituents of the mixture were placed in the thin wall of PCR tube and run 
using PCR machine. Hot-start was performed by heating the tube at 95ºC for two 
minutes, 30 cycles of 95ºC for 0.30 seconds, Tm (see Table 3.4) for 0.30 seconds, 72ºC 
for 0.30 seconds and 72ºC for 10 minutes before cooling down to 4ºC. All the positive 
colonies which amplified via colony PCR were analysed through 0.7% agarose gel 
electrophoresis (Section 3.7.1) 
Table 3.4: PCR profile  
 
PCR  Temperature  
95ºC 2 minutes 
95ºC 0.30 seconds 
64ºC 0.30 seconds 
72ºC 0.30 seconds 
72ºC 10 minutes 
 
Positive colonies (colonies carrying the vector and gene) were grown up in 
kanamycin broth to amplify the construct and for storage as glycerol stock for future.  
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3.28 Plasmid Analysis 
The overnight culture was extracted as mentioned in the (Section 3.20). In order to 
confirm the presence of the insert of the expression clone, the plasmid DNA were subjected 
to restriction endonuclease digestion as described in the section (Section 3.23) using the 
same enzyme, HindIII-HF and BamHI-HF. Both extracted plasmid and digested sample 
were subject to electrophoresis using 1% agarose gel (Section 3.7.2). 
3.29 DNA sequencing and Basic Local Alignment Search Tool (BLAST) 
The purified plasmid was sent for sequencing at MyTaccg Bioscience Enterprise as 
the confirmation ABA392 in pET-30a protein expression system. The sequencing 
service took approximately three days to obtain the chromatogram raw data with the 
nucleotide sequences. The obtained chromatogram raw data was analyzed through 
sequence scanner software known as BIOEDIT in order to retrieve the nucleotide 
sequence.  
3.30 Blast Search  
The nucleotide sequences obtained from the BIOEDIT were confirmed using 
BLAST search from NCBI website (www.ncbi.nih.gov).  
3.31 ABA392/pET-30a DNA Stability Test 
Before induction, a single positive colony of ABA392/pET-30a was cultured in 10ml 
broth containing kanamycin/chloramphenicol for overnight. The overnight culture was 
transferred to new 10ml LB broth with vigorous shaking until it reached an OD600 of 
0.6. Serial dilution was conducted on the cell suspension from 101 to106. Cells at 
dilution 105 were plated on LB with IPTG agar (Section 3.5.7) and LB plate/ 
kanamycin/chloramphenicol/ IPTG agar (Section 3.5.8).  
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Cells at dilution 106 was plated LB agar plate (Section 3.5.2) and LB with 
kanamycin/chloramphenicol (3.5.6). Plates were than incubated overnight at 37ºC. The 
numbers of colonies in each plate were counted on next day. 
3.32 Protein Analysis 
3.32.1 Protein Induction 
Colony from positive clone (ABA392/pET-30a) in LB agar with 
kanamycin/chloramphenicol plates (Section 3.27) was inoculated in to a 10 ml of LB 
broth containing kanamycin/chloramphenicol and incubated at 37ºC overnight. The 
10ml overnight culture was then inoculated into 50ml pre-warmed broth with vigorous 
shaking until it reached an OD600 of 0.6 in about 60 to 120 minutes. 1ml sample was 
immediately taken before induction, this sample served as the non-induced control, the 
cells were centrifuged at 5000 rpm for 5 minutes  and supernatant were removed as 
much as can. The cells were than resuspended with 50µl 1X PBS (Section 3.11.2) and 
50ul 2x sample buffer (Section 3.13.8) and heated for 10 minutes at 95ºC on heating 
block. The non-induced control was frozen and stored at -20ºC until SDS-PAGE was 
performed. Expression was induced by adding IPTG (Section 3.11.1) to a final 
concentration of 0.1mM. The culture was then incubated further for an additional 4-5 
hours at 37ºC. following the incubation, 1ml sample was taken, the cells were 
centrifuged at 5000 rpm for 5 minutes  and supernatant were removed as much as can. 
The cells were than resuspended with 50µl PBS and 50µl 2x sample buffer and heated 
for 10 minutes at 95ºC on thermal block. The induced control was frozen and stored at -
20ºC until SDS-PAGE was performed. The remaining induced cells were harvested by 
centrifugation at 3500 x g 4ºC for 60 minutes and then the cell pellets were frozen and 
stored overnight at -20ºC. 2µL of lysozyme (Section 3.11.4) and 2µL of DNAase 1 
(Section 3.11.4) is added to 1mL of B-PER reagent (Section 3.11.3).  The overnight 
induced frozen pellets were thawed on ice for 15 minutes. The pellets were weighed and 
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4ml of B-PER® reagent were added per gram of cell pellet. The suspension was pipetted 
up and down until it is homogenous and incubated 10-15 minutes at room temperature. 
The lysate was centrifuge at 3500 rpm for 30 minutes to separate soluble proteins from 
the insoluble proteins (Noor Masyitah Jumahat et al., 2015). The cell lysate supernatant 
was retained and the supernatant contains the soluble fraction of the recombinant 
protein. 5µl of the supernatant (cell lysate) is aliquot and added with 5µL 2x SDS-
PAGE sample buffer and stored at -20ºC for SDS-PAGE analysis (Section 3.32.3).  
3.32.2 Purification of 6xHis-tagged Proteins 
350µl of Cell lysate that containing histidine-tagged protein was mixed with 350µl of 
1X binding/wash buffer (Section 3.12.1) in total volume of 700µl. Dynabeads (Section 
3.12.1) was thoroughly resuspended in the vial by vortex it for 30 seconds. 50µl (2mg) 
of Dynabeads was transferred into a 1.5ml microcentrifuge tube and placed on a magnet 
for 2 minutes. The supernatant was aspirated and discarded. The total 700µl of cell 
lysate which mixed with 1x binding/wash buffer was added to the beads and mixed 
well. It was then incubate on a roller for 5 minutes at room temperature. The tube was 
then placed on the magnet for 2 minutes and the supernatant was discarded. The beads 
were washed for 4 times with 300µl binding/wash buffer by placing the tube on a 
magnet for 2 minutes and supernatant was discarded. The beads were resuspended 
thoroughly between each washing step. On the washing step is done, 100µl of His-
Elution buffer (Section 3.12.3) was added and incubated on a roller for 5 minutes at 
room temperature. The tube was applied on magnet for 2 minutes and the supernatant 
containing the eluted histidine-tagged protein was transferred to a clean tube. Each 
fraction including the elution fraction was collected in a separate 1.5ml microcentrifuge 
tube. 5µl of each fraction was added with 5µl 2X sample buffer and heat at 95ºC for 5 
minutes before sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis (Section 3.32.3) was about to perform. The entire fraction was stored at -20ºC.  
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3.32.3 Protein Separation Technique by SDS-PAGE 
Protein separation was conducted via sodium dodecyl sulfate polyacrylamide gel 
electrophoresis technique (SDS-PAGE) technique. SDS-PAGE separates proteins 
according to their respective molecular weight. The SDS-PAGE method is one 
dimensional gel electrophoresis. This method was based on Laemmli (1970). In this 
study, SDS-PAGE was performed using Mini-PROTEAN Electrophoresis units with a 
power supply. Gel was prepared according to below formulation (Table 3.5): 
Table 3.5: SDS-PAGE gel formation 
 
Formulation Stacking gel 
(4%) 
Resolving gel 
(12%) 
Deionized H2O 3.4ml 6.1ml 
30% Acrylamide (Section 3.13.1) 4.0ml 1.3ml 
1.5 Tris (pH 8.8) (Section 3.13.2) 2.5ml - 
0.5 Tris-HCl (pH 6.8) (Section 3.13.3) - 2.5ml 
10% SDS (Section 3.13.4) 0.1ml 0.1µl 
Ammonium persulphate (APS) 
(Section 3.13.5) 
50µl 50µl 
TEMED (Section 3.13.6) 5µl 10µl 
 
The protein sample was analyzed using SDS-PAGE.  The apparatus for the SDS-
PAGE were set by assembling one clean spacer glass plate and clean short plate. It was 
locked and secured by using green clamps. The prepared 12% resolving gel (Table 3.5) 
was poured into the glass plates using a micropipette along the edge one of the spacers 
to a height of 1cm below glass margin. The separating gel was covered with distilled 
water and the gel was left to polymerize for 30 to 60 minutes at room temperature. Once 
the gel polymerized, the distilled water was removed. Once all the distilled water was 
drained out 4% stacking gel (Table 3.5), solution were prepared and poured slowly 
using a micropipette along the edge of the spacer to the top of the sandwich glass plate. 
A 1.0mm teflon comb was inserted into layer of stacking gel solution and it was left to 
polymerize at room temperature for 30 to 45 minutes. On a clean flat surface, the 
clamping frame on the electrode assembly is opened. The electrode assembly (with the 
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banana plugs) is use when running only 1-2 gels. The first gel cassette (short plate 
facing inward) molded into the bottom of the clamping frame assembly surface. The 
second gel is placed on the other side of the clamping frame again by resting the gel 
onto the supports. The gel was pulled towards each other gently in order to make the gel 
rest firmly and squarely against the green gaskets in the clamping frame. The gel 
cassette was squeezed against the green caskets, the green arms of the clamping was 
slide over the gels and locked them into the place. The gel cassette was placed on the 
tank. The comb was removed from the stacking gel and wells were filled with running 
buffer (Section 3.13.7) for loading samples. The samples were mixed with sample 
buffer (Section 3.13.8) in ratio 1: 1. Samples mixture were incubated at 95ºC for 5 
minutes and loaded into the respective wells including protein ladder (Section 3.13.9). 
Running buffer was poured into the gel tank and the gel tank was connected to the 
power supply. The electrophoresis was performed using power supply at 120 volts for 
75 to 85 minutes. The power supply was turned off when the dye front reaches 
approximately 1 cm from the bottom of the gel. After electrophoresis, the gels were 
stained using colloidal coomassie staining method. The gel were placed on 100ml of 
colloidal coomassie solution (Section 3.13.10) in a plastic container then placed on a 
shaker for overnight. Once the gel stained for overnight, the de-staining process was 
carried out to wash out the excess dye. The coomassie blue staining was poured out and 
100 ml of de-staining solution (Section 3.13.11) was added and placed on the shaker for 
about 30 minutes. The gel was subject to de-staining process few times until a clear 
background was obtained.  
3.32.4 Protein Quantification 
The Bio-Rad DC protein assay (Section 3.13.12) is a colorimetric assay for protein 
concentration following detergent solubilisation. This reaction was adapted Lowry 
Assay (1951) with slight modification. This assay was based on the reaction of protein 
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with alkaline copper tartrate solution and folin reagent. 20µl of reagent S was added to 
reagent A which will be needed for the run. Dilution of protein standard containing 
from 0.2mg/ml to 1.4mg/ml (Table 3.6) was prepared from 10mg/ml BSA solution 
(Section 3.13.12.1). 5µl of standards and samples were pipetted into a clean, dry 
microtiter plate. 25µl of reagent A was added into each well followed by 200µl of 
reagent B into the each well. The microtiter plate was gently agitated to mix the 
reagents. The absorbance was reads at 650nm 15 minutes later. 
Table 3.6: Preparing of BSA Standard Curve from BSA Concentration 
10mg/ml 
 
Tube 
Number 
1 2 3 4 5 6 7 8 
Protein 
concentration 
(mg) 
0 0.2 0.4 0.6 0.8 1 1.2 1.4 
Volume of 
10mg/ml BSA 
(ml) 
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 
Sterile 
Mili-Q 
Water (ml) 
1 0.98 0.96 0.94 0.92 0.9 0.88 0.86 
 
3.33 Western Blot Analysis 
Eluted-His Tag protein and marker were run SDS- Gel as described Section 3.32.3. 
Four piece of filter paper and a piece of membrane (0.45µm nitrocellulose) was cut to 
the same size as the gel. The SDS-PAGE gel with eluted His-tag protein and protein 
marker was placed on blotting buffer (Section 3.14.1) for 15 minutes. The membrane 
was incubated in blotting buffer for 10 minutes. The filter paper and membrane was 
soaked in blotting buffer. 2 sheets of filter paper was placed on the fiber pad followed 
by the gel, membrane, 2 sheets of filter paper and finally the other fiber pad without 
trapping any air bubbles. Once the transfer sandwich was assembled, the blot was 
placed on the cathode and the gel placed on the anode. The cassette was placed on 
transfer tank filled with blotting buffer and ice block is placed on the tank. Blotting 
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transfer is done at 100V for 1 hour. The blot was soaked in 5% blocking buffer (Section 
3.14.2) at 4ºC overnight. Ponceau S staining can be done in order to check the transfer 
quality but it is an optional step. After overnight incubation, the blot was washed with 
TBST (Section 3.14.4) 3 times under shaking condition for 10 minutes at room 
temperature each time. Primary antibody was prepared by mixing 5ml of 2.5% skimmed 
milk (Section 3.14.5) with 1µl of Penta Anti-His antibody (Section 3.14.7) under 1:5000 
dilution. The blot was soaked in primary antibody for 1 hour at room temperature under 
shaking condition. Once the incubation period was over, the washing step was repeated 
as described previously. Secondary antibody was prepared by 5ml of 2.5% skimmed 
milk with 1µl anti mouse IgG, AP-linked antibody (Section 3.14.7) under 1:5000 
dilution The blot was soaked in secondary antibody for 1 hour at room temperature 
under shaking condition. Once the incubation period was over, the washing step was 
repeated as described previously. Finally, the blot was soaked with 1ml of 5-Bromo-4-
Chloro-3-indolyl phosphate (Section 3.14.6) under dark condition. The membrane was 
dried and visible band was photographed.  
3.34 Animal Immunogenicity Test 
3.34.1 Bacterial Suspension 
The preparation of bacterial suspension for vaccine was adapted with slight 
modification (Hussaini et al., 2012). A single pure bacterium was grown overnight at 
37ºC in 10 ml of BHI broth medium. The cultures were then centrifuged for 30 minutes 
at 3500 rpm to pellet the cells. The pelleted cells were washed three times with sterile 
PBS to remove all traces of the growth medium. The cells were resuspended in 5ml of 
PBS pH 7.2 to achieve the concentration of 107 colony forming units CFU. Formalin 
concentration 0.2% was added. The cell suspensions were left to stand  for overnight  
and centrifuged at 3500 rpm for 30 minutes, the supernatant  replaced by an equal 
volume of fresh 0.2% formalinized PBS. About 1ml of the inoculum was spread onto 
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blood agar and BHI agar as confirmation that the bacteria have been killed. The bacteria 
suspension was then allocated into 1.5ml microcentrifuge tube and stored at -20ºC prior 
to use. This formalin killed vaccine serve as positive control.  
3.34.2 Experimental Animals 
Twelve white rats, Sprague Dawley of female rats weighing 150g-200g were used 
for this part of research. Rats were purchased from Animal Experimental Unit (AEU), 
Faculty of Medicine, and University Malaya. The animals were housed in individual 
clean cage at the experimental room, Animal House, University Malaya. All the rats 
were feed a commercial food along with water. Rats were kept under observation for 
two weeks before research were conducted. This research was approved by Institutional 
Animal Care Use Committee (IACUC), University Malaya prior to the research under 
ethic number of ISB/18/11/2015/RDVM (R).   
3.34.3 Immunization of the Rats  
Rats were divided causally into 4 different groups where 3 rats in each group. All the 
rats were inoculated subcutaneously with the proper amount according to the body 
weight (Diehl, 2001). To determine the immunogenicity of purified protein from 
ABA392/pET-30a, group 1 was given purified protein of ABA392/pET-30a (50µg) and 
group 2 rats were treated with ABA392/pET-30a (100µg). Group 3 serve as positive 
control which given formalin killed vaccine meanwhile group 4 was the negative 
control where the rats in this group were given sterile PBS. The vaccination was carried 
out in two dose schedule. In this two dose schedule the rats were immunized on day 
zero and followed by 2nd booster were given two weeks later via subcutaneously route. 
Blood was collected on day 1st, 7th, 14th, 21st, 28th and 35th. At the end of the 
immunization, rats were sacrificed by overdose anaesthesia following the animal ethic 
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requirement. Serum were separated by centrifuging at 13,000 x g for 20 minutes, pooled 
and stored at -20ºC until it was used.  
 
 
Figure 3.1: Timeline of animal immunization studies 
 
3.34.4 Haematological and Biochemical Studies 
For haematological studies, the blood was collected via tail and on day 35th was 
collected via cardiac puncture. The rats were bled on day 0, 7th, 14th, 21st, 28th and 35th 
(Figure 3.1). Total white blood cell (WBC) was performed as observation tools. 10µl of 
fresh blood was added to 190µl of Turks solution (1: 20 dilution) mixed and then loaded 
into a haemocytometer and the total white blood cells were counted under microscope 
using cell counter (Oli et al., 2016). The cells were counter under microscope using 
differential cell counter. For biochemical analysis, blood were collected via cardiac 
puncture and serum separated. Serums were then send to Division of Laboratory 
Medicine, PPUM for liver function test (LFT) and renal function test (RFT). Results 
were obtained within 2 days.   
59 
3.34.5 Organ Collection 
The different needed organs of the animals were collected upon dissection. Autopsy 
was performed on the rats and organs after the dissection. All the collected organs were 
placed on 10% NBF (Section 3.15.4) in a clean collection container in order to preserve 
for histopathological analysis.  
3.34.6 Histopathological Analysis 
All the organs were trimmed before they were processed. All the tissue samples were 
processed manually. After the overnight fixation process, the fixative solution is 
discarded in an appropriate waste bottle. The tissues were immersed through a series of 
ethanol with ascending concentration (70% >85% >95%> 100%) for 30 minutes in 
order to remove all the water that remained in the tissue. The tissues were immersed in 
100% ethanol for 45 minutes twice. These whole processes were done in room 
temperature. Once the dehydration process is done, the tissues were immersed in xylene 
for 3 hours. Once the incubation period over, the small bottles with tissue were filled 
with melted from tissue embedding centre and kept at in an oven at 60ºC for 2 hours. 
After 2 hours, the paraffin is changed and the tissue is kept at in an oven at 60ºC for 
overnight. The steps involved in the processing of the tissues are shown in the Figure 
3.2. Once the tissue was being processed, the tissues were embedded into paraffin 
blocks using tissue embedding machine (Histo Embedder Leica, Japan). The paraffin 
blocks were kept at room temperature for overnight to form as solid blocks. The solid 
blocks were trimmed before can be sectioned. The trimmed paraffin tissue blocks were 
section at 6µm using Leica RM2035 microtome and a sharp microtome blade for best 
result. The cut section of tissue were gently placed on a clean glass slide that contains a 
smear of Meyer’s albumin (Section 3.15.5) and water in order to adhere the section 
tissues. It was make sure there is no air bubbles were not trapped under the paraffinized 
tissue section. The slides the placed on a slide warmer with 42ºC temperature for 15 to 
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20 minutes before placing the slides into oven for 24 to 36 hours.  This will help the 
section adhere completely and melt the wax.  
 
Figure 3.2: Serial steps involved during tissue processing 
3.34.7 Histopathology Staining 
Histopathology staining that were used in this research is Harris Haematoxylin 
(Section 3.15.6.1) and Eosin Y (Section 3.15.6.2) staining (H&E). The initial step of the 
staining is started by de-paraffin the slides followed by hydration to remove the excess 
of xylene. Slides were washed with distilled water before staining with haematoxylin. 
The washing step is repeated again before the slides were stained with Eosin. 
Subsequently after staining the slides, the slides were dehydrated. Finally the clearing 
process by passing through xylene is done followed by mounting. The H&E steps 
followed as Figure 3.3.  
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Figure 3.3: Subsequential step involved in H&E Staining 
3.35 Indirect Enzyme Linked Immunosorbent Assay (ELISA)  
ELISA was developed based on the procedure by Okay et al., (2012) with slight 
modification. ELISA was performed on the hyper-immune sera obtained from 
immunized rat for the presence of antibody. The optimization of the antibody for IgG 
was optimize and determined at the ratio of 1: 2,500. ELISA plate, 96-well plate with 
flat bottom was coated with 50µL/well of coating antigen (Section 3.16.2) and 
incubated at 4ºC overnight. After overnight the incubation period, the coating antigen 
was discarded gently and washed with 50µL/well sterile washing buffer-PBS-Tween 20, 
pH 7.4 (Section 3.16.3) for 2 times. Once the washing step done, 200µL/well of sterile 
blocking buffer-PBS-Tween 20-BSA, pH 7.4 (Section 3.16.4) was added and incubated 
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at 37ºC for 1 hour. Serum dilution was diluted in ratio 1:50 and was prepared during the 
incubation period. After the incubation time over, the blocking buffer was discarded 
gently and washing step was repeated as previously. About 50µL/well of serum 
(primary antibody) was added and the plate was incubated at 37ºC for 1 hour. After 
incubation period, the serum was discarded gently and washing step repeat as 
previously. 50µL/well of IgG antibody conjugate (Section 3.16.7) was added and 
incubated for 1 hour at 37ºC. Antibody conjugate was discarded gently and washing 
step repeated as previously. 100µL/well of tetramethylbenzidine (TMB) substrate 
(Section 3.16.5) was added and incubated at 37ºC for 15 minutes. As the last step and to 
stop the reaction, 50µL/well of stopping buffer (Section 3.16.6) was added. Finally the 
absorbance was read at 450nm on a microtiter plate reader. All standards, samples, 
positive and negative controls were used in triplicates.  
3.36 Statistical Analysis 
Data were analyzed by SPSS version 20 (2011) using Independent T-Test (Salmah 
Ismail et al., 2012 and Singh et al., 2011) and Microsoft Excel throughout this study.  
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CHAPTER 4: RESULT 
 
4.1 Purification and RE Digestion of ABA392/pUC57 
Figure 4.1 (a) shows purified ABA392/pUC57 where the size shows ~3.5 kb in lane 
2 and 3. The appearance of nicked/relaxed circular plasmid can be seen in white box.  
Meanwhile figure 4.1 (b) shows the digested ABA392 from puc57 using HindIII-HF 
and BamHI-HF restriction enzymes in lane 2 and 3. The correct digested ABA392 result 
is 804 bp.  
                                 
Figure 4.1: 1% Gel electrophoresis (a) shows purified ABA392 gene (b) shows 
digested ABA392 gene 
Figure 4.1 (a) Lane 1, Invitrogen Supercoiled DNA ladder and lane 2 to 3, purified 
ABA392/pUC57. The purified ABA392/pUC57 size was determined approximately 
~3.5 kb. Appearance of nickel/relaxed circular plasmid can been seen in white box. 
Figure 4.1 (b) Lane 1, GeneRuler 1 kb plus ladder and lane 2 to 3, digested 
ABA392gene with RE HindIII-HF and BamHI-HF. The digested ABA392 gene size 
was at 804 bp. 
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4.2 Isolation and Digestion of Vector pET-30a 
Figure 4.2 shows isolated and digested vector pET-30a.  Lane 1 shows marker, lane 2 
purified pET-30a vector and lane 4 and 5 show digested pET-30a vector using HindIII-
HF and BamHI-HF restriction enzyme at the correct size at 5422 bp. The appearance of 
nicked/relaxed circular plasmid can be seen in white box. 
 
Figure 4.2: 1% Gel electrophoresis shows isolated and digested pET-30a 
 
Lane 1, Invitrogen 1 kb plus DNA ladder; lane 2, purified pET-30a vector; lane 3, 
NIL; lane 4 to 5, digested pET-30a vector with RE HindIII-HF and BamHI-HF. The 
purified and digested pET-30a vector size was determined at size of 5422 bp. There are 
appearance of nicked/relaxed circular plasmid that can be seen in white box.  
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4.3 Gel Extraction of Digested ABA392 Gene and pET-30a 
Figure 4.3 shows gel extraction of digested ABA392gene and pET-30a vector. Lane 
1 was loaded with marker, lane 2 and 3 show gel extraction of digested ABA392 gene at 
size of 804 bp meanwhile lane 4 and 5 show gel extraction of digested pET-30a vector 
at size of 5422 bp. This extracted gene and vector was ligated and transformed into E. 
coli BL21 (D3) pLysS. 
 
 
Figure 4.3: 1% Gel electrophoresis shows gel extraction of ABA392 gene and pET-30a 
vector 
 
Lane 1, GeneRuler 1 kb plus ladder; lane 2 to 3, gel extraction of digested 
ABA392 gene and lane 4 to 5, gel extraction of digested pET-30a vector. The extracted 
of digested ABA392 gene and pET-30a vector shows size of 804 bp and 5422 bp 
respectively. 
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4.4 Cloning ABA392 Gene into pET-30a Expression Vector 
The ABA392 gene and vector was double digested with the restriction enzyme 
HindIII-HF and BamHI-HF. Figure 4.3 shows extracted digested ABA392 and pET-30 
vector was ligated between HindIII-HF and BamHI-HF restriction sites. The ligated 
vector was then transformed into E. coli BL21 (DE3) pLysS host to be expressed. 
Figure 4.4 (a) shows positive transformants of the colony had been grown in normal and 
concentrated LB agar with kanamycin 30µg and 34µg chloramphenicol and Figure 4.4 
(b) shows negative control was done by just replacing the ligated product with a sterile 
distilled. Figure 4.4 (c) shows potential transformants were subsequently patch plated 
on fresh LB kanamycin/chloramphenicol and the positive clones were further screened 
using colony PCR and confirmed the presence of the insert.  
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Figure 4.4:  LB agar with kanamycin (30 µg) and chloramphenicol (34 µg) plate (a) 
shows positive tranformants of ABA392/pET-30a in E. coli BL21 pLysS (b) shows 
negative control (c) shows ABA392/pET30a colony library plate 
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4.5 Colony PCR Screening  
The positive clones were further screened using colony PCR. The size of insert was 
determined through gel electrophoresis. Figure 4.5, lane 1 show marker, lane 3 to 10 
shows the band with the size of around 804 bp from positive colony screening and no 
visible band in control lane 11 
 
 
Figure 4.5: 0.7% Gel electrophoresis shows colony screening of ABA392/pET-30a 
through colony PCR 
 
Lane 1, GeneRuler 1 kb plus ladder; lane 2, Nil; lane 3 to 10, PCR product positive 
colony which contain ABA392 gene and lane 11, negative control. PCR product show 
positive colony that contain ABA392 gene at size 804 bp.. 
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4.6 Recombinant Plasmid Isolation 
The plasmid was than extracted from the positive transformants. RE digestion was 
carried out as reconfirming the presence of the insert and sent for sequencing. Double 
digestion of the clone with the two RE, HindIII-HF and BamHI-HF using cut smart 
buffer.  This RE digestion generated the clone into two fragments, an insert and the 
vector.  Figure 4.6 (a) shows ABA392/pET30a recombinant plasmid isolation, lane 1 is 
marker and lane 2 to 3 purified ABA392/pET-30a size of 6.2 kb. Figure 4.6 (b) shows 
the ABA392 gene (insert) was digested from pET-30a vector, lane 1 is marker and lane 
2 to 3, digested ABA392/pET-30a. The correct digested ABA392 gene show the size of 
804 bp meanwhile pET-30a vector size was 5422 bp. The appearance of nicked/relaxed 
circular plasmid is circled in white meanwhile circular/single stranded plasmid is circled 
in yellow box.  
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Figure 4.6: 1% Gel electrophoresis (a) shows isolation of recombinant plasmid of 
ABA392/pET-30a (b) shows digested of ABA392/pET392 through restriction enzyme 
analysis 
Figure 4.6 (a) Lane 1, Invitrogen Supercoiled DNA ladder and lane 2 to 3, purified 
ABA392/pET-30a. The purified ABA392/pET-30a size shows approximately ~ 6.2 kb. 
There are appearance of nicked/relaxed circular plasmid that can be seen (white box) 
and circular/single stranded plasmid that can be seen in (yellow box). Figure 4.6 (b) 
Lane 1, Gene Ruler 1 kb plus ladder and lane 2 to 3, digested ABA392/pET-30a. The 
digested ABA392 shows size at 804 bp and pET-30a vector show size at 5422 bp. 
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4.7 DNA Sequencing of ABA392/pET-30a 
As to reconfirm the presence of the insert ABA392 gene, the isolated was send for 
sequencing. The sequencing was than analysed using BIOEDIT software and obtained 
sequence was compared using the available database. BLAST (Basic Local Alignment 
Search Tool) was one of the tool used to compare between pairs of obtained sequences 
and search for region of local similarity. BLAST was accessed from National Centre for 
Biotechnology Information (NCBI) similarity with the native ABA392 recombinant 
clone.  Figure 4.7 (a) show chromatogram raw data from the sequencing result. Figure 
4.7 (b) show the sequence found from the chromatogram raw data. The sequence 
highlighted in bold and underlined is the alignment of nucleotide of recombinant 
plasmid ABA392/pET-30a which has the same identical sequence PMB202 through 
BLAST application at NCBI (Accession No. DQ334273).  Figure 4.7 (c) and (d) shows 
the query sequence that had 100% similarity with the reference sequence FJ001839.1 in 
BLAST.  
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 (a) 
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GAG ATG GCA TAT GAG TCT TTT GTT CTG TCG CTT GTC GAA 
GAG AGT GTT GAG CTG GCT AAC GAG CAT AGA CTG ATA CTT 
CTT GAG CTA GGT AGC CGT CTT TTT TTG AGT GCT GAG CCG 
GTT TTC AGG GCG GAC TTC CTA CAA GTG GCC GAG AAG TAT 
CTA AAT AGG CTT GGC TGA TAC GAT TCT TAT CGC TTT CCA 
CAG AGC CCA AAT AAG GCA CTT GCT TCA TTT GAG ATT CTC 
TGC CAA GAC TAG GGC TCC CTC CTC TGA TCG CTT CAA GCC 
CAT GAC CAA GCC GAC CGG CAG ACA CAG GAT GAC TCA GTA 
GGG GCC GGG GCG ATG GAA TAC GGC ATA GAA ATC GAG 
ATC ATG ACC GCC ATT GCG AAA ATC AGC AGG GAT TGT GTG 
CGC GAC TCT TGC CCC GCG TAT TGG CGC ATT ACC ATC GGA 
ATA TCA GGT CCT CAA GGA ACA GTA TCC CGA GCA GTA GGG 
CGC GAC ACT CGA CAA CCT GCT ACG CAA GAT AGC AGC TGC 
GAT CCG CAG CTG AAG CAA CCT GCC AGT CCC GAT AAG AGC 
CCG GTA GAC ATC CTT TAC CAT ACC GAT CAC TTG GGC ACG 
CCG AGG GAG CTG ACC GAC AAG GAT GCC GCA GTC TAA GTC 
GCG ACG TAC AAG GCA TGG GGT AAC ACG GTG AAG ATC 
GAG CGG CCT GGA CGA CTG ACC ACC GAT ATC CAA GGC AAT 
GGT CCA GAT CCT GTC TTC GCC GAC ATG GGC GCC TCG CTG 
GTC GAC GAC GCC AAC CCG GTG CAG GAC TTC GCC GCC CAT 
GTG CCC AAC ATG GCG GGT TTC CAC CGC CGC TAG ATG GCC 
AGC AAC CGC GCC TGC CCT TCT GGG TGC AGA TGG TGC GCG 
AGA TGG ACG TGG CCA TGA CGT CCC CAG CAC GGG CCG GCC 
CTT CGT CGG GTG GCG AGA TGA TC 
(b) 
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(c) 
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Figure 4.7: Sequencing Analysis of Recombinant Clone ABA392/pET-30a (a) shows 
chromatogram raw data from the sequencing results (b) shows the sequence found from 
the chromatogram raw data (c) and (d) shows the query sequence that had 100% 
similarity with the reference sequence FJ001839.1 in BLAST 
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4.8 Recombinant Plasmid ABA392/pET-30a DNA Stability Test 
Before induction, fractions of cells that carry the target plasmid were determined. 
Plating of recombinant plasmid ABA392/pET-30a was done in four different plates 
with two replicates for each plate. Figure 4.8 shows cells grown on four different plates. 
Plate 1 shows cells were grown on LB agar plate, plate 2 show cells were grown on LB 
agar with kanamycin/chloramphenicol, plate 3 shows cells were grown on LB agar with 
IPTG and plate 4 shows cells were grown on LB agar with 
kanamycin/chloramphenicol/IPTG. Table 4.1 shows the number of cells that were 
grown in each plate.    
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Figure 4.8: Shows ABA392/pET-30a DNA stability testing 
 
Recombinant clone ABA392/pET-30a grown in four different plates: plate 1, LB 
agar plate; plate 2, LB agar with kanamycin/chloramphenicol; plate 3, LB agar with 
IPTG and plate 4, LB agar with kanamycin/chloramphenicol/IPTG 
 
 
Table 4.1: Shows number of cells in each different four plates of ABA392/pET-30a 
DNA stability testing with 2 replicates for each plates 
Number of Cells 
Types of Plates Plate 1 Replicate 
Plate 1 
Replicate 
Plate 2 
LB agar plate 423 410 420 
LB agar with 
kanamycin/chloramphenicol 
401 375 370 
LB agar with IPTG 58 58 65 
LB agar with 
kanamycin/chloramphenicol/IPTG 
0 0 0 
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4.9 Separation of purify His-Tag Protein of Recombinant Plasmid 
ABA392/pET-30a by SDS-PAGE 
Recombinant plasmid ABA392/pET-30a was induced and purified using His-Tag 
isolation and pulldown. Figure 4.9 shows purified his-tag protein of recombinant 
plasmid ABA392/pET-30a, lane 1 is marker, lane 2 is cell lysate of recombinant 
plasmid ABA392/pET-30a, lane 3 is flow through fraction of recombinant plasmid 
ABA392/pET-30a, lane 4 to 7 is wash fraction (1-4) of recombinant plasmid 
ABA392/pET-30a and lane 9 to 10 is eluted His-tag protein of recombinant plasmid 
ABA392/pET-30a shows the approximate size of the recombinant protein determined to 
be ~32 kDa 
 
 
Figure 4.9: Analysis of ABA392/Pet-30a 6xHis-tagged protein expression in E. coli   
BL21 (DE3) pLysS using Dynabeads His-Tag Isolation and Pulldown 
 
Lane 1, Protein prestained ladder; lane 2, cell lysate; lane 3, binding protein, lane 4 to 
5, wash fraction 1-4 and lane 9-10, extracted His-tag recombinant protein approximately 
~32 kDa (arrow). The transformed ABA392/pET-30a plasmid was induce with IPTG 
thus protein were expressed. The expressed was purified through affinity 
chromatography by using Dynabeads His-Tag Isolation and Pulldown and size were 
determined from SDS-PAGE, approximately ~32 kDa. 
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4.10 Protein Quantification of Eluted Protein of Recombinant Plasmid 
ABA392/pET-30a 
Eluted His-tag protein from recombinant plasmid ABA392/pET-30a was quantified 
using DC protein assay. Lowry assay was adapted to quantify his-tag protein from 
recombinant plasmid ABA392/pET-30a and the concentration of 0.5mg/ml was 
determined.  
 
Figure 4.10: Graph showing protein standard curve constructed by DC protein    assay 
using BSA as a standard 
 
Table 4.2: Absorbance reading for the protein standard and protein sample 
 
Protein Concentration (mg/ml) Absorbance 
(650nm) 
0 0.001 
0.2 0.063 
0.4 0.096 
0.6 0.145 
0.8 0.156 
1 0.177 
1.2 0.252 
1.4 0.295 
His-tag protein of ABA392/pET-30a 0.095 
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4.11 Immunoblotting of the Expressed Protein 
The expressed his-tag recombinant protein was subjected to immunogenic detection 
by using immunoblotting method. Figure 4.11 shows expressed His-tag protein on 
nitrocellulose membrane, Lane 1 is marker and lane 2 shows expressed His-tag 
recombinant protein of ABA392/pET-30a at size of ~32 kDa. 
 
 
Figure 4.11: Western blot analysis with Penta Anti-His Antibody  
 
Lane 1, Protein prestained ladder and lane 2, expressed His-tag recombinant protein.          
The expressed His-tag protein on nitrocellulose membrane shows approximately ~32 
kDa.  
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4.12 Animal Immunogenicity Test  
4.12.1 Gross Pathological Analysis 
Upon dissection, gross pathological analysis was done for each organ, lung, heart, 
kidney and liver collected from each group.  
   
 
 
 
Figure 4.12: Gross pathological analysis for each organ, lung, heart, kidney and liver 
from (a) shows each organ from rats vaccinated with ABA392/pET-30a (50µg), (b) 
shows each organ from rats vaccinated with ABA392/pET-30a (100µg) and (c) shows 
each organ from rats vaccinated with PBS-negative control 
There were no significant changes were observed in all organs from each group. 
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4.12.2 Histopathology Analysis 
Histological slides were prepared from all the organs collected from group 1, group 2 
and group 4. Each slide was stained with hematoxylin and eosin (H&E). Sign of 
haemorrhage, inflammation, congestion or was observed in all the tissues.  
Histopathological analysis of the collected organs is summarized in Table 4.3.  
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Figure 4.13: Histopathological section of the lungs from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(50µg) with 20x magnifications, 50µm 
 Nucleus appears to be normal and slight thickening wall of alveoli with red blood 
cell (RBC) presents. No inflammation cells or haemorrhagic were observed.  
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Figure 4.14: Histopathological section of the heart from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(50µg) with 20x magnifications, 50µm 
 
Nucleus appears to be normal. Cardiac muscle shows branches and cardiac muscle 
cells with normal looking nucleus. No inflammation cells or haemorrhagic were 
observed.  
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Figure 4.15: Histopathological section of the liver from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(50µg) with 20x magnifications, 50µm 
Nucleus and central vein appears to be normal. No inflammation cells or 
haemorrhagic were observed.  
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Figure 4.16: Histopathological section of the kidney from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(50µg) with 20x magnifications, 50µm 
Nucleus, proximal convoluted tubule (4. 16(a) ) and distal convoluted tubule (4.16(b) 
) appears to be normal. No inflammation cells or haemorrhagic were observed.  
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Figure 4.17: Histopathological section of the lungs from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(100µg) with 20x magnifications, 50µm 
Nucleus appears to be normal and slight thickening wall of alveoli with red blood 
cell (RBC) presents. No inflammation cells or haemorrhagic were observed. 
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Figure 4.18: Histopathological section of the heart from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(100µg) with 20x magnifications, 50µm 
Nucleus appears to be normal. Cardiac muscle shows branches and cardiac muscle 
cells with normal looking nucleus. No inflammation cells or haemorrhagic were 
observed. 
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Figure 4.19: Histopathological section of the liver from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(100µg) with 20x magnifications, 50µm 
Nucleus and central vein appears to be normal. No inflammation cells or 
haemorrhagic were observed. 
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Figure 4.20: Histopathological section of the kidney from (a) rats vaccinated with PBS 
(negative control) and (b) rats vaccinated with purify protein from ABA392/pET-30a 
(100µg) with 20x magnifications, 50µm 
Nucleus, glomerulus and proximal convoluted tubules appear to be normal. No 
inflammation cells or haemorrhagic were observed. 
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Table 4.3: Summary of histopathological analysis of the collected organs from rats 
vaccinated with ABA392/pET-30a (50µg & 100µg) and PBS (negative control) 
Animal Group of the Histopathology Analysis 
Organ ABA392/pET-
30a (50µg) 
Negative 
Control-PBS 
ABA392/pET-
30a (100µg) 
Lung  Nucleus 
-appear to be normal 
Alveoli 
-slight thickening 
with the present of 
Red Blood Cell 
(RBC) 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Alveoli 
-slight thickening 
with the present of 
Red Blood Cell 
(RBC) 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Alveoli 
-slight thickening 
with the present of 
Red Blood Cell 
(RBC) 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Heart Nucleus 
-appear to be normal 
Cardiac muscle 
-shows branches 
with normal nucleus 
cells 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Cardiac muscle 
-shows branches 
with normal nucleus 
cells 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Cardiac muscle 
-shows branches 
with normal nucleus 
cells 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Liver  Nucleus 
-appear to be normal 
Central vein 
-normal  
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Central vein 
-normal  
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Central vein 
-normal  
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Kidney Nucleus 
-appear to be normal 
Distal convoluted 
tubules appears  
 -normal 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
Nucleus 
-appear to be normal 
Glomerulus  and 
proximal 
convoluted tubules  
-normal 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
 
Nucleus 
-appear to be normal 
Glomerulus  and 
proximal 
convoluted tubules  
-normal 
Inflammation 
-No inflammation 
cells were identified 
Haemorrhagic 
-None 
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4.12.3 Total White Blood Count (WBC) 
Table 4.4: Total WBC count and significance of values among rats vaccinated with 
ABA392/pET-30a (50µg), ABA392/pET-30a (100µg), killed bacterin (positive control) 
and PBS (negative control) 
 
Animal 
Group 
No. of animal Type of 
Vaccination 
T. White Blood 
Count 
(Means ±SE) 
Significance 
Group 1 3 ABA392/pET-
30a 
(50µg) 
9107(2007)a 
Group 2 3 ABA392/pET-
30a 
(100µg) 
10250(1908)a 
Group 3 3 Positive control-
Killed bacterin 
7876(1914)a 
 
Group 4 3 Negative control-
PBS 
3760(268)b 
All values are expressed as mean ± Standard Error (SE). n=3, mean with different 
super scripts are significantly differences p<0.05.  
 
 
 
 
Figure 4.21: Graph shows the mean WBC count of different groups and their treatment 
for past 6 interval week 
Comparison on total WBC from rat vaccinated with purified protein from 
ABA392/pET-30a (50µg and 100µg) compared with rat vaccinated with normal saline 
and killed bacterin P. multocida serotype B. Each points shows means of total WBC 
count of three pooled serum sample from three individual rats (n=3) and bar represents 
SE value (p<0.05).  
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Total WBC was performed on the blood collected from Sprague Dawley rats of the 
entire groups for each interval week. Figure 4.21 shows, group 1 (ABA392/pET-30a, 
50µg), group 2 (ABA392/pET-30a, 100µg), group 3 (killed bacterin, positive control) 
and group 4 (PBS, negative control). From the graph, it shows that group 1, 2 and 3 had 
slight constant line increase of total white blood count compare to group 4. All the 
collected data was analysed using independent t-test using SPSS. Result are expressed 
as mean ± standard error (SE), n=3 in each group. The first immunization was given in 
the first week, group 1 and group 3 shows to have increased in the total white blood 
count, but there were no significant differences were observed till the second booster 
immunization was given. After the second booster immunization was given at week 3, 
the graph started to show leukocytosis from week 4 to 6. There were statistically 
significance differences (p<0.05) between week 5 and 6. The rats in negative control 
which was injected sterile PBS did not show any significance increase in leucocyte 
count. Table 4.4 shows, as compared between treatments groups with positive control 
there were no significance differences were observed meanwhile there were 
significantly different in comparison between treatment groups and negative control. 
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4.12.4 Liver Function Test (LFT) 
Table 4.5: Serum level of liver function test (LFT) among rats vaccinated with 
ABA392/pET-30a (50µg), ABA392/pET-30a (100µg), killed bacterin (positive control) 
and PBS (negative control) 
 
Parameter 
Animal 
Group/ 
No. of 
animal 
Type of 
Vaccination 
Albumin  
g/L 
Alkaline 
Phosphatase 
(ALP) 
Umol/L 
Alanine 
Aminotransferase 
(ALT) 
U/L 
Total 
Bilirubin 
U/L 
G-Glutamyl 
Transferase 
(GGT) 
U/L 
Group 1/ 
(3) 
ABA392/pET-
30a (50µg) 
40.00±0.577a 203.33±19.751a 40.67±4.055 a 2.00±0.00 6.00±0.00 
Group 2/ 
(3) 
ABA392/pET-
30a (100µg) 
38.33±0.667a  179.67±.9.684a 36.33±3.667 a 2.00±0.00 6.00±0.00 
Group 3/ 
(3) 
Positive 
control-Killed 
bacterin  
40.67±1.202a 159.00±3.055 a 40.67±2.963 a 2.00±0.00 6.00±0.00 
Group 4/ 
(3) 
Negative 
control-PBS 
41.33±0.882a 158.00±24.021a 52.67±18.809 b 2.00±0.00 6.00±0.00 
Results are presented as mean ± SE. p<0.05.  
SE value for both group total bilirubin and G-Glutamyl Transferase is 0. 
 
 
 
 
Figure 4.22: Graph shows the mean of liver function test (LFT) of different group 
The liver function test parameters that were involved are albumin, Alkaline 
Phosphatase (ALP), Alanine Aminotransferase (ALT), total bilirubin and G-Glutamyl 
Transferase (GGT). Comparison on serum activities of LFT parameters from rat 
vaccinated with purified protein from ABA392/pET-30a (50µg and 100µg) compared 
with rat vaccinated with normal saline and killed bacterin P. multocida serotype B. Each 
points shows mean of serum activities of three pooled serum sample from three 
individual rats (n=3) and bar represents SE value (p<0.05).   
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Liver function test (LFT) was performed on the blood collected from Sprague 
Dawley rats of each group on day 35. Figure 4.22 shows, group 1 (ABA392/pET-30a, 
50µg), group 2 (ABA392/pET-30a, 100µg), group 3 (killed bacterin, positive control) 
and group 4 (PBS), negative control). All the collected data was analysed using 
independent t-test using SPSS. Result are expressed as mean ± SE, n=3 in each group. 
The serum level of activities of albumin, Alkaline Phosphatase (ALP), Alanine 
Aminotransferase (ALT), total bilirubin and G-Glutamyl Transferase (GGT) in 
experimental animal is shown on Table 4.5. Serum activities of albumin, ALP, total 
bilirubin and GGT in all the treatment group and control groups were in normal value. 
There was no statistically significant differences were observed in serum activities of 
albumin and ALP between treatment groups and negative control groups (p>0.05). 
There were statistically significant differences were observed in serum activities of ALT 
between treatment groups and negative control groups (p<0.05). Serum activities of 
ALT in treatment group were in normal value meanwhile slightly higher was observed 
in negative control.  
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4.12.5 Renal Function Test (RFT) 
Table 4.6: Serum level of renal function test (RFT) among rats vaccinated with 
ABA392/pET-30a (50µg), ABA392/pET-30a (100µg), killed bacterin (positive control) 
and PBS (negative control) 
 
Parameter 
Animal 
Group/ 
No. of 
animal 
Type of 
Vaccination 
Sodium 
mmol/L 
Potassium 
mmol/L 
Chloride 
mmol/L 
Urea 
mmol/L 
Creatinine 
umol/L 
Group 1/ 
(3) 
ABA392/pET-
30a (50µg) 
141.33±2.906a 6.133±0.5457a 100.00±2.082a 6.200±0.4163a 30.67±2.186a 
Group 2/ 
(3) 
ABA392/pET-
30a (100µg) 
139.67±1.453a 6.000±0.4163a 99.00±1.528a 6.400±0.5568a 28.00±1.000a 
Group 3/ 
(3) 
Positive 
control-Killed 
bacterin  
137.67 ±3.333a  5.233±0.2906 a 97.00±2.517 a 6.833±0.2404a 27.33±0.667a 
Group 4/ 
(3) 
Negative 
control-PBS 
140.67±1.764a 5.333±0.3180 a 98.33 ±2.404 a 7.467±0.3667a 32.00±1.528a 
Results are presented as mean ± SE. p>0.05. 
 
 
 
 
Figure 4.23: Graph shows the mean of renal function test (RFT) of different group 
The renal function test (RFT) parameters that were involved are sodium, potassium,   
chloride, urea and creatinine. Comparison on serum activities of RFT parameters from 
rat vaccinated with purified protein from ABA392/pET-30a (50µg and 100µg) 
compared with rat vaccinated with normal saline and killed bacterin P. multocida 
serotype B Each points shows mean of serum activities of three pooled serum sample 
from three individual rats (n=3) and bar represents SE value (p>0.05). 
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Renal function test (RFT) was performed on the blood collected from Sprague 
Dawley rats of each group on day 35. Figure 4.23 shows, group 1 (ABA392/pET-30a, 
50µg), group 2 (ABA392/pET-30a, 100µg), group 3 (killed bacterin, positive control) 
and group 4 (PBS, negative control). All the collected data was analysed using 
independent t-test using SPSS. Result are expressed as mean ± SE, n=3 in each group.  
The serum level of activities of sodium, potassium, chloride, urea and creatinine in 
experimental animal is shown on Table 4.6. Serum activities of sodium, potassium, 
chloride, urea and creatinine in all the treatment group and control groups were in 
normal value. There were no statistically significant differences (p>0.05) were observed 
in serum activities of sodium, potassium, chloride, urea and creatinine among all the 
groups.  
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4.12.6 ELISA 
Table 4.7: ELISA OD reading using 450nm performed on serum from rat vaccinated 
ABA392/pET-30a (50µg), ABA392/pET-30a (100µg), killed bacterin (positive control) 
and compared with rat vaccinated PBS (negative control) 
Animal Group No. of animal  Type of 
Vaccination  
ELISA OD 
(means ±S.E.M) 
Signifcance 
Group 1 3 ABA392/pET-30a  
(50µg) 
0.099(0.015)a 
Group 2 3 ABA392/pET-30a  
(100µg) 
0.081(0.007)a 
Group 3 3 Positive control-
Killed bacterin  
0.071(0.012)a 
 
Group 4 3 Negative control-
PBS 
0.045(0.009)b 
All values are expressed as mean ± SE. Mean with different super scripts are 
significantly differences p<0.05. 
 
 
 
Figure 4.24: ELISA O.D Analysis Using 450nm 
Comparison on serum IgG from rat vaccinated with purified protein from 
ABA392/pET-30a (50µg and 100µg) compared with rat vaccinated with normal saline 
and killed bacterin P. multocida serotype B. Each points shows mean of serum activities 
of three pooled serum from three individual rats (n=3) and bar represents SE value 
(p<0.05).  
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The development of the immunoglobulin (IgG) antibody response in Sprague 
Dawley rats was analysed using ELISA. From Figure 4.24, graph shows group 1 which 
was treated ABA392/pET-30a (50µg) had slightly higher development IgG compare to 
overall other groups. Group 3 which were treated with killed bacterin thus serve as 
positive control has also develops IgG from week 3 towards to week 6. Among all the 
groups, group 1 shows constant of development of antibody compare to other remaining 
groups. Once the first immunization was given on week 1st no development was 
observed but when the 2nd booster was given on week 3, the chart shows increase in the 
IgG level in all groups expect for the negative control group. All the collected data was 
analysed using independent t-test using SPSS. Result are expressed as mean ± SE, n=3 
in each group. There were no significance differences after the 1st immunization was 
given. When the second booster was given on 3rd week the level IgG antibody were 
increase and statistically significant differences were observed from week 3 to 6 
(p<0.05). Table 4.7 shows comparison between treatments groups (ABA392/pET-30a 
(50µg and 100µg) with positive control (killed bacterin). There is no significance 
differences were observed between the two groups. Meanwhile, there were significantly 
difference in comparison between treatment group (ABA392/pET-30a (50µg and 
100µg) ) and negative control (PBS), 0.099, 0.081 and 0.045 respectively. As compared, 
positive and negative treatments show significant differences in the level of IgG which 
can be due to non-specific immunity induced in the white rats. There were no doubts in 
the ELISA results obtained and rats treated with two doses of vaccine showed to be 
effective in developing antibody.  
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CHAPTER 5: DISCUSSION 
 
5.1 Cloning ABA392 into Protein Expression Vector 
ABA392 gene was successfully cloned into pET-30a, an expression vector. In order 
to complete this transformation process, purified ABA392 gene (Figure 4.1 (a) ) and 
pET-30a (Figure 4.2) vector was digested using restriction enzyme (RE). The RE 
composition consists of two identical polypeptide subunits joined together to form a 
homodimer. This homodimer is known as short symmetric DNA sequences of 4 to 8 bp 
whereby 6 bp is ideal for cloning. The function of this enzyme is to recognize specific, 
short and nucleotide sequence on a double-stranded DNA molecule which is known as 
restriction site and cleaved it accordingly (Mullis, 1990). The RE digested ABA392 
gene in Figure 4.1 (b) and pET-30a vector (Figure 4.2) were ligated using DNA ligase. 
DNA ligase together with ATP which function as cofactor forms a phosphodiester bond 
between ABA392 gene and pET-30a vector was ligated and this process known as 
ligation (Allison, 2007). This ligation mixture was introduced into bacterial cells (E. 
coli BL21 (DE3) pLysS) and the process known as transformation. The E. coli BL21 
(DE3) pLysS was incubated in concentrated calcium salt solution in order to make the 
membrane leaky. This solution was mixed with the ligation mixture and was allowed 
into the bacterial cell. Successfully transformed bacteria carried both recombinant and 
non-recombinant plasmid DNA. The tranformants were plated on LB agar with 
kanamycin/chloramphenicol and those bacteria that have recombinant DNA plasmid 
only will grow on the plate (Figure 4.4 (a) ). The selection of transformant selection was 
based on the growth of the colonies on plate that containing both 
kanamycin/chloramphenicol) (Sambrook et al., 1989).  For the colony library) the 
colony PCR was conducted from patch plate (Figure 4.4 (c) ) to detect the presence of 
ABA392 gene inserts in pET-30a vector using the synthesized primer where the 
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ABA392 gene were at 804 bp (Figure 4.5). Two positive colonies were extracted and 
show the expected size the clone carrying the insert. The clone size were determined to 
be 6.2 kb (Figure 4.6 (a) ). RE digestion was carried out on extracted clone using 
HindIII-HF and BamHI-HF where the insert (ABA392gene) at 804 bp and vector (pET-
30a) at 5422 bp were observed (Figure 4.6 (b) ). To reconfirm the presence of the insert 
ABA392 gene, the extracted clone was send for sequencing. The result from DNA 
sequencing confirmed the presence of ABA392 gene in the recombinant and raw data 
was used for homology and nucleotide sequence analysis by identifying the similar 
based through BLAST application at NCBI (Figure 4.7 (a), (b) and (c) (d). 
5.2 Plasmid Stabilty testing of ABA392/pET-30a 
Before induction, the culture was determined for the fragment of cells that still carry 
the targeted plasmid. This process started with plating the cells on four different plates 
and done in triplicate for each plate (Figure 4.8). Cells grown on LB agar were viable 
cells. Cells that grown on LB agar with kanamycin/chloramphenicol are the cells that 
still carry the plasmid meanwhile, cells that grown on LB agar with IPTG shows the 
cells that have lost the plasmids on mutants. This lost leads to the disability of 
expressing the targeted gene. Finally cells that grown on LB agar with 
kanamycin/chloramphenicol/IPTG shows only mutant that contain the plasmid which 
lost the ability to express the target gene. The existence of IPTG causes all the energy is 
being used for the production of recombinant protein instead of maintaining the cell that 
has the plasmid for protein production.  
5.3 Protein Induction and Purification 
The recombinant plasmid ABA392/pET-30a was transformed into an expression host 
E. coli Bl21 (DE3) pLysS bacterial strain which specially design for expression of genes 
that controlled by T7 promoter. This pET-30a expression was mainly chosen due to T7 
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promoter, kanamycin resistant and multiple cloning sites. pET-30a vector will be more 
suitable for the cloning and expression of recombinant protein in E. coli purpose. Since 
E. coli is a nontoxic host and this being an important reason for many recombinant 
protein being expressed hence it is being used as generally in research industry as an 
expression host (Farhangnia, 2014). The present of T7 promoter in pET-30a is very 
important and compromising during targeted recombinant protein production. When the 
interested gene is cloned behind T7 promoter and it is recognized by T7RNA 
polymerase (T7 RNAP) which can be found in bacterial genome. Protein from this pET-
30a expression system can be expressed by inducing using IPTG (Rosano & Ceccarelli, 
2014). IPTG addition will induce and prompt protein expression. T7 RNA polymerase 
production after the induction will particular transcribe the coding sequence of the 
protein of interest which is inserted into the expression vector which restraint by T7 
promoter (Briand et al., 2016). Sequences that encoding six histidine presence at 5’ of 
the multiple cloning sites (MCS) and this is the most significant reason on choosing this 
pET expression vector (Fang, 2006).  
E. coli BL21 (DE3) pLysS has lysogenic cycle and λ-DE3 which encode T7RNA 
polymerase and control by lacUV5 promoter. The compatible plasmid pLysS carries the 
gene encoding T7 lysozyme which reduces the background expression level of the 
targeted gene. This is controlled by T7 promoter and expression level is achieved 
without any interference during IPTG induction (Rosano & Ceccarelli, 2014). 
After induction, the expressed protein from ABA392/pET-30a was purified using 
cobalt-based Immobilized Metal Affinity Chromatography (IMAC). The principle of 
this purification is based on magnetic separation where consist a simple step. The 
magnetic carrier which can be consist of an immobilized affinity, magnetic biopolymer 
particles, hydrophobic ligand or ion exchange groups has an affinity towards to the 
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isolated substances. The magnetic carrier will be mixed with a sample. This sample can 
be from crude protein as well. During the incubation duration, the target substances 
which have affinity tag towards the magnet carrier will bind to each another. This 
magnetic complex can be eluted using magnet separator after a few washing steps. This 
magnetic separation technique is very simple conduction steps involved and due to the 
magnetic propertied it easily removed from the samples. This process is very gentle to 
obtain the targeted proteins and effective for large scale purification (Safarik & 
Safarikova, 2004). IMAC can purify highly expressed protein and can provide purified 
tagged protein in single purification step. Using IMAC the polyhistidine-tagged protein 
can be also purified under mild condition without altering the biological activity. 
Purified protein from IMAC can be also further purified using other chromatographic 
method in future (Bornhorst & Falke, 2000).  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is an 
important method to separate protein. Protein is separated based on their movement 
capability which depends on the length of polypeptide chain or molecular weight when 
place on electrical current. SDS function as removing secondary and tertiary protein 
structure in order to maintain the protein as polypeptide chain (Roy & Kumar, 2014). 
Laemmli system is the most extensively SDS-PAGE gel system that has been used to 
separate the protein. It uses tris-glycine gels which composed of stacking gel and 
resolving gel. Both have two different principle in separating the protein where stacking 
gel component will aid focusing the protein into sharp bands during the initial phase of 
the electrophorectic run meanwhile resolving gel with the different acrylamide 
percentage will separate the protein bands on their the mass weight (Laemmli, 1970).  
To find the molecular weight of the expressed clone, ABA392/pET-30a recombinant 
plasmid was subjected to SDS-PAGE. Before performing induction, colony from 
positive clone (ABA392/pET-30a) was culture on a LB kanamycin/chloramphenicol 
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plates (Section 3.27) was inoculated in to a 10ml of LB broth containing 
kanamycin/chloramphenicol and incubated at 37ºC overnight. The 10ml overnight 
culture was then inoculated into 50ml pre-warmed broth with vigorous shaking until it 
reached an OD600 of 0.6 in about 60 to 120 minutes. 1 ml sample was immediately taken 
before induction, this sample served as the non-induced control, the cells were 
centrifuged at 5000 rpm for 5 minutes  and supernatant were removed as much as can. 
The cells were then re-suspended with 50µl 1X PBS (Section 3.11.2) and 50ul 2x 
sample buffer (Section 3.13.7) and heat for 10 minutes at 95ºC on heating block. The 
non-induced control was frozen and stored at -20ºC until SDS-PAGE was performed. 
Expression was induced by adding IPTG (Section 3.11.1) to a final concentration of 
0.1mM. The culture was then incubated further for an additional 4-5 hours at 37ºC. 
following the incubation, 1ml sample was taken, the cells were centrifuged at 5000 rpm 
for 5 minutes  and supernatant were removed as much as can. The cells were then re-
suspend with 50µl 1X PBS and 50µl 2x sample buffer and heat for 10 minutes at 95ºC 
on thermal block. The induced control were frozen and stored at -20ºC until SDS-PAGE 
was performed. The remaining induced cells were harvested by centrifugation at 3500 x 
g 4ºC for 60 minutes and then the cell pellets were frozen and stored overnight at-20ºC. 
The cells were lysis using B-PER reagent (Section 3.32.1). The cell lysate was then 
purified using Dynabeads His-Tag Isolation and Pulldown) which based on cobalt-based 
Immobilized Metal Affinity Chromatography (IMAC) (Section 3.32.2). 6x His-tag has 
been used extensively to purify recombinant protein due to applied a low metabolic 
burden on expression host and provide flexible condition for IMAC (Dan et al., 2009).  
Cobalt-based Immobilized Metal Affinity Chromatography (IMAC) has the ability to 
display less non-specific protein binding compare to nickel and due to this it has 
increased the purity of eluted protein (Bornhorst & Falke, 2000). The entire collected 
fraction was subjected to SDS-PAGE. The gel was the stained with colloidal coomassie 
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solution (Section 3.13.10) in a plastic container for overnight followed by destaining 
(Section 3.13.11). The gel was wash 2 to 3 times until a clear background was obtained. 
Following the SDS-PAGE analysis, size of the expressed protein from recombinant 
clone ABA392/pET-30a was determined to be at ~32 kDa (Figure 4.9). The nucleotide 
sequence (Appendix F) of ABA392/pET-30a was then translated into six reading frame 
of amino acid using the translation programme. This translation programme was 
provided by Expert Protein Analysis System (ExPASy) (Abdul Latif et al., 2017). 
Among the protein blasted result from all the frame, amino acid (267aa) from 3’5’ 
frame 1 (Appendix G) showed 93% similarity (252/272 aligned) with ABA392 clone 
(P. multocida) (Appendix H). Translation of six histidine residue (HHHHHH) was 
founded along with the inserted protein. The molecular weight of the expressed 
recombinant protein from ABA392/pET-30a was analysed using the ExPASy pI/Mw 
Tool (Appendix I). It was comparable to the purified expressed recombinant protein 
from ABA392/pET-30a with a molecular weight approximately around 32 kDa. Protein 
which has more than 100 amino acids has the potential to be a functional protein 
(Salmah Ismail et al., 2012). During the protein purification, some of the non-specific 
protein which was not able to bind to the resin will be discharged through the flow-
through solution along with the washing buffer. The existence of several protein bands 
at the lane of eluted His-tag protein (lane 9 & 10) in Figure 4.9 might be due to some of 
the contaminant proteins which were eluted together with the protein of interest. As the 
protein was expressed in low intensity, some background protein contamination may be 
observed (Abdul Latif et al., 2017). This may occur when the purification of low level 
His-Tag recombinant protein in E. coli system using IMAC which frequently result in 
co-eluted with some contaminant protein from the host cells (Robichon et al., 2011). 
The low intensity of the expressed protein with background contaminant can be referred 
to the instability of targeted protein which has the potential to be degraded or weak 
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bound to the resin. In this similar case, the recombinant might be lost easily due to the 
gap between chromatography resins with irreversible adsorption of non-specific region 
of the targeted protein. In conjunction with this, the expressed His-Tag protein might be 
decrease in the final elution step (Abdul Latif et al., 2017). Meanwhile, the non-tagged 
protein which from the host cell has higher chance to bind together with the resins and 
eluted together with background contamination in case there is a failure in targeted 
recombinant protein binding to the resins (Chirstensen et al., 2007). To overcome this 
problem, mass spectrometry can be conducted along to identify the targeted expressed 
His-tag protein as well.  
5.4 Protein Quantification 
To quantify the purified protein, Bio-Rad DC protein assay was used. This assay 
was adapted from Lowry assay with slight modification. In Lowry assay, the reaction 
between protein and copper occur in an alkaline medium and followed by reduction of 
the folin reagent by the copper-treated protein. Colour was developed due to the amino 
acids tryptophan and tyrosine and reduction in amount of cystine, cysteine and histidine 
(Lowry et al., 1951). The concentration of purify protein was 0.5mg/ml were obtained 
(Figure 4.10). 
5.5 Immunoblotting of Expressed His-tag Protein of ABA392/pET-30a 
Immunoblotting was carried out in order to confirm the expression of 6xHis-tagged 
of ABA392/pET-30a.  Western blot is the most common immunoblotting technique to 
separate and identify proteins. First the protein was separated by molecular weight using 
SDS-PAGE followed by transferring the membrane which has a band for each protein. 
The membrane then was incubated with specific antibodies to the targeted protein. The 
bound antibody to the targeted protein only will be left and the unbound antibody after 
the washing step and these bound antibodies can be exposed in the film (Mahmood & 
Yang, 2012). The western blot procedure can recognize the recombinant plasmids that 
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express a 6xHis-tagged protein since there is short his-tag peptide sequence encoded by 
pET-30a protein expression vector. The eluted purify his-tag protein was run SDS-
PAGE gel. After transferring the eluted his-tag protein of ABA392/pET-30a to 
nitrocellulose membrane, his-tagged protein had reacted positively with Penta Anti-His 
antibody and anti-mouse IgG, AP-linked antibody. A band was visible at ~32 kDa size 
on the film (Figure 4.11). Thus, His-tag protein is successfully expressed and it was 
ready to for further analysis.  
5.6 Histopathology Analysis 
Histopathological studies were performed on both groups of ABA392/pET-30a and 
negative control groups. Upon gross pathological examination, there were no significant 
changes were noticed on the site of injection of ABA392/pET-30a (50µg or 100µg) 
vaccinated. There were no allergy reaction or lesion arise which suggest a good tissue 
uptake characteristics of the protein vaccine (Figure 4.12 (a)-(b) ). There was no sign of 
HS like haemorrhage, inflammation cells, oedema or hyperaemia were found in the 
lung, heart, liver or kidney (Figure 4.13 (a) - 4.20 (b) ) (Chung et al., 2015). The 
histopathological analysis was summarized in Table 4.3. This finding signifies that 
ABA392/pET-30a protein vaccine does not cause any visible changes to the host. 
Invisible of any histopathological changes that observed in ABA392/pET-30a 
vaccinated group when compared with control group, it can be suggested a safety use of 
the expressed protein as a vaccine since it has not shown any toxicity effect on the tissue 
especially on the site of administration. Previously, Hussaini et al. (2011) stated that, 
when ABA392 clone was injected to rats, HS symptoms were observed. Gross 
pathology analysis demonstrated severe multiple abscess were observed in parenchyma. 
Meanwhile, histopathological analysis showed severe parenchyma congestion of the 
lungs along with the presence of inflammatory cells and haemorrhagic were observed in 
few vital organs like spleen, lungs and liver.  
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5.7 Haematology Analysis and Biochemical Analysis 
The haematological analysis shows increased in WBC count from week 1 towards 
week 6. Total WBC shows leukocytosis (Figure 4.21). There is a significant different 
were observed between treatment group when compare to control group (p<0.05). There 
are two types of immunity, innate and adaptive or both. Innate immunity is known as 
body’s first line protection which is rapid, non-specific, and presents during exposure to 
foreign texture. Meanwhile adaptive immunity, when there is successive exposure to 
foreign texture there will be increased defensive response of the immune system (Vogel, 
2010). The biochemical analysis in this study is being effective parameters to reveal an 
impairment functional capacity of organs.  
 The liver function test ( LFT) in this studies was conducted to see the impacts of 
the vaccinated rats with ABA392/pET-30a (50µg and 100µg) on the liver function 
enzyme parameter such as albumin, Alkaline Phosphatase (ALP), Alanine 
Aminotransferase (ALT), total bilirubin and G-Glutamyl Transferase (GGT) in order to 
assess the hepatotoxic potential of this recombinant vaccine (Figure 4.22). The obtain 
result of ALP, ALT, total bilirubin, and GGT of treated with recombinant protein 
vaccine ABA392/pET-30a (50µg and 100µg) groups were in normal value. Meanwhile, 
histopathology examined of liver tissue also show no degenerative changes in both 
treatment groups (Figure 4.15 (b) and 4.19 (b) ). Hepatic injury is often correlated with 
alteration in the serum and liver of some enzyme particularly ALT, AST and ALP 
(Whitby, 1984). Renal function tests (RFT) are mandatory to examine the presence or 
absence lesion in the kidney. RFT in this study was conducted to see the impacts of the 
vaccinated rats with ABA392/pET-30a (50µg and 100µg) on the renal function test 
parameters of sodium, potassium, chloride, urea and creatinine (Figure 4.23). Mild 
hyperkalaemia were observed in both treatment groups meanwhile hypernatremia was 
not observed. Sodium, chloride, urea and creatinine of treated with recombinant protein 
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vaccine ABA392/pET-30a (50µg and 100µg) group were in normal value. 
Histopathology examined of kidney tissue also show no degenerative changes in both 
treatment groups (Figure 4.16 (b) and 4.20 (b) ). 
5.8 Immunogenicity Study of Expressed Protein from ABA392/pET-30a 
The ABA392 gene was successfully clone into pET-30a protein expression vector, the 
protein was induced and his-tag protein was purified. The expressed his-tag protein 
were reconfirmed via immunoblotting analysis by using Penta Anti-His antibody and 
anti-mouse IgG, AP-linked antibody. Immunogenicity of expressed protein of 
ABA392/pET-30a was distinguished. Rat was chosen due to its larger size. Besides that, 
the availability to perform surgical procedures and the involvement of proportional size 
of important substructures in the organ and affected level (Lannaccone & Jacob, 2009). 
Moreover, rats offer the capacity to collect large amount of blood (up to1.5ml) at one 
time. This amount of blood allows multiple assays at one time (Lee & Goosens, 2015). 
According to Fish (2008), female are affected more compare to male in disease that 
involved with immune response and display more strong cell-mediated and humoral 
response to antigenic challenge. Besides that, in order to correct the exclusion of female 
rats in research and to reduce the bias of using male rats is one of the reasons of using 
female rats in this research (Beery & Zucker, 2011). 150g-200g female Sprague Dawley 
were used and immunized with 2 dose where first immunization were given on 1st day 
followed by 2nd booster on day 14th with two different 50µg and 100µg 
protein/rat/subcutaneous injection.  Rats were observed daily and blood was collected 
every week for total white blood count (WBC). The vaccinated rat with expressed 
protein from ABA392/pET-30a (50µg and 100µg) shows significantly induced higher 
antibody titers compared to PBS (negative control) and formalin killed bacterin 
(positive control) (Figure 4.24). All the collected data were analysis using independent 
t-test. Further, it was observed from primary vaccination with ABA392/pET-30a, a 
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significant increase can be seen only after week 3 when second booster was given. It 
shows that IgG response is more rapid and significant by 14 day after the second 
booster is given on week 3 (Hodgson et al., 2005). The increased of antibody can only 
be seen after the second booster were given which begin after week 3 and started to 
increase for the next two weeks. Even though administration of recombinant protein 
vaccine has the capability to prompt immune response against pathogen after being 
expressed by plasmid or harmless bacteria but it shows weak or low immune response. 
Thus, it sometimes requires the usage of an adjuvant in order to provoke protective and 
last long term immunity. The main problem encountered during development of new 
adjuvant is not only involving to understand their molecule complexity but also the 
mechanism of the immune response activation (Nascimento & Leite, 2012). The same 
observation was made by Yasin et al. (2011), when using the expressed recombinant 
protein vaccine from fimbrial protein of P. multocida B: 2 whereby, the antibody level 
gradually rise and increased significantly for the next 2 weeks which can be seen at 
week 3 and 4 after the booster dose was given. This might be due the primary 
vaccination was unable to boost the memory cells to produce a significant level of 
secondary antibody thus a booster dose was required (Yasin et al., 2011). Another 
possibility, a booster is required when the vaccine might be degraded rapidly by the host 
defense mechanism without giving the memory cells to copy the vaccine material 
(Isaguliants et al., 2004). Further, significant difference was observed among sera from 
rat vaccinated ABA392/pET-30a compare to both positive and negative group (p<0.05) 
which able to provoke humoral immune response against recombinant plasmid (Singh et 
al., 2011; Salmah Ismail et al., 2012). Sera from formalin killed vaccine have been 
observed and show the significance difference when compared to the negative control. 
This is due to the formalin killed vaccine have the same homologus potency as 
inactivated vaccine. The immunity may have obtained half from host specific and 
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bacterium itself which cause ineffective and short immunity thus became the 
disadvantage of this killed vaccine. Recombinant vaccine which known as third 
generation vaccines and has specific aspect in producing vaccine against P. multocida. 
Identified virulence and immunity gene from P. multocida has a promising in the 
recombinant protein vaccine production (Ahmad et al., 2014). The first recombinant 
vaccine was developed in 1994 using a non-toxic recombinant derivative of the P. 
multocida toxin (rPMT) has induced response against rhinitis is pig (Bording et al., 
1994). Okay et al. (2012), has stated recombinant created using 3 different fusion of 
gene, P1pE or OmpH and lipoprotein E (P1pE) genes have shown high competency and 
can be used as vaccine for cattle against P. multocida infection. A recombinant protein 
vaccine using a gene that encoding VacJ outer membrane lipoprotein of P. multocida B: 
2 strain p52 was developed. This vaccine has provoked humoral response thus can be a 
potential vaccine candidate against pasteurellosis in livestock (Shivachandra et al., 
2014) 
5.9 Limitation of Study 
 In this study, the protective properties of this vaccine candidate were not being 
able to carry out to the vaccinated animals in order compare with other currently 
available vaccine. This is due to lack of supportive facilities to carry out the challenge 
tests as P. multocida serotype B: 2 is classified under Class 3 biohazard organism and 
must be treated with very much care to avoid unnecessary infection to the involved 
personnel.  
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CHAPTER 6: CONCLUSION 
 
6.1 Conclusion 
This study was carried out to express protein from ABA392/pET-30a and focused on 
the immune response of the expressed protein for vaccine production against HS. In 
order to expressed the protein and discover the capability of the gene, ABA392 gene 
was cloned to expression system. ABA392/pET-30a recombinant plasmid was 
successfully constructed by ligating ABA392 gene into pET-30a expression system and 
transformed into E. coli BL21 (DE3) pLysS bacterial strain. The 6x His-tagged 
recombinant protein from ABA392/pET-30a was successful expressed due to tagging 
ABA392 gene in N/C-Terminal of pET-30a vector. The expressed protein was then 
purified using cobalt-based Immobilized Metal Affinity Chromatography (IMAC) 
system and was confirmed by immunoblotting method. The expressed and purified 
protein size was determined as ~32 kDa from the SDS-PAGE. Immunogenicity of the 
ABA392/pET-30a recombinant plasmid was determined as discussed in Chapter 5. The 
purified protein from ABA392/pET-30a is being immunogenic and has capability to 
produce high titer antibody. Simultaneous immunization, no shock or other 
inflammation were observed in vaccinated animals. At the site of injection, there is no 
inflammation or any other changes were visible. This discovery indicates that 
ABA392/pET-30a as vaccine does not cause any apparent changes to the host. This 
characterization shows ABA392/pET-30a have a potential to be a vaccine candidate in 
future.  
 In this study protective properties of the vaccine candidate in the vaccinated 
animal which involving challenging with P. multocida serotype B: 2 was not able to 
carry out. This is due P. multocida serotype B: 2 is classified under Class 2 biohazard 
and there is lack of supportive facility to carry out the protective efficacy part and in 
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order to avoid unnecessary infection to the personnel involved and other laboratory 
experimental animals.  
 Since the expressed protein has the capability to provoke immune response, 
challenge studies using P. multocida serotype B: 2 against this protein are required to 
enhance the efficient of this protein as a vaccine against HS in future. Thus, the protein 
could be used in development of ELISA kit for identification of P. multocida serotype 
B: 2 during sudden outbreak as diagnostic tool.   
 To discover the full effectiveness of the clone, the assurance and efficacy of the 
protein in cattle or buffalo will be targeted as future study. Certain characteristics of the 
vaccine need to be looked into as a measurement the efficient and safety of the vaccine 
such as the route of immunogenicity of the vaccine under local condition, route of 
administration, standard of vaccine delivery method and appropriate dosage according 
body weight. Besides that, studies must be conducted on immune response from new 
vaccine and existing HS vaccine to compare the effectiveness. 
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APPENDIX 
Appendix A: Online news article from myMetro 
 
 
Appendix A: Online news article from myMetro dated on 6th June 2017 reported the 
death of 245 farm animal including cattle and buffalo due to HS at Kuala Terengganu  
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Appendix B:  Online news article from Astro Awani 
 
Appendix B: Online news article from Astro Awani dated on 11th June 2017 reported 
the latest occurrence of HS and also stated it is under control at Kuala Terengganu  
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Appendix C: Map of protein expression vector pET-30a 
 
Appendix C:  pET-30a a bacterial expression vector (size of 5422 bp) which consist of 
T7 promoter, kanamycin resistant gene and multiple cloning sites 
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Appendix D: Steps involved during recombinant cloning and protein 
expression from ABA392/pET-30a recombinant clone.  
 
Appendix D: Steps involved in cloning ABA392 gene into pET-30a protein expression 
vector and transformation into E. coli BL21 (D3) pLysS. ABA392/pET-30a is then 
induce and recombinant His-tag protein is expressed 
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Appendix E: ABA392/pET-30a DNA stability testing 
 
 
Appendix E: ABA392/pET-30a DNA stability testing replicate plate 1 and 2 
Recombinant clone ABA392/pET-30a grown in four different plates: plate 1, LB agar 
plate; plate 2, LB agar with kanamycin/chloramphenicol; plate 3, LB agar with IPTG 
and plate 4, LB agar with kanamycin/chloramphenicol/IPTG 
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Appendix F: Nucleotide Sequence of Recombinant Clone ABA392/pET-30a 
 
Appendix F: Nucleotide sequence of ABA392/pET-30a fragment in the size of 6229 bp 
which will be translated to amino acid sequence 
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Appendix G: Amino acid sequence translation of expressed protein from 
recombinant clone ABA392/pET-30a 
 
Appendix G: Translation of amino acid sequence into six reading frames where six 
histidine residue (HHHHHH) along with the inserted protein were found at frame 3’5 
frame 1 
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Appendix H: Protein BLAST search of protein translation from 3’5 Frame 
1 
 
Appendix H: Translation amino acid sequence of recombinant clone ABA392/pET-30a 
from 3’5 Frame 1 showed 93% similarity (252/272 aligned) same identical sequence of 
ABA392 (P. multocida) through protein BLAST at NCBI ( accession number 
ACF60959.1) 
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Appendix I: Molecular weight estimation of protein translation protein 
from recombinant clone ABA392/pET-30a  
 
Appendix I: The theoretical molecular weight of expressed recombinant protein from 
ABA392/pET-30a, ~32 kDa (32123.10 Da) 
  
